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ABSTRACT 
Purpose: To investigate the best carrier technology for our β-amyloid (Aβ) 
aggregation inhibitors by developing three types of liposomes (a) plain liposomes, (b) 
MAL-PEG liposomes, and finally the combination of retro-inverted peptide RI-OR2-
TAT (Ac-rGffvlkGrrrrqrrkkrGyc-NH2) attached onto the surface of MAL-PEG 
liposomes, creating Peptide Inhibitor Nanoparticles (PINPs) of three different sizes 
(50, 100 and 200 nm). In addition, these nanoliposomes (NLPs) (with particular focus 
on PINPs) were examined for their ability to affect Aβ aggregation, and to protect 
against Aβ cytotoxicity. 
Methods: The creation of NLPs was carried out by the use of a mini extruder, while 
the elution of PINPs from a size exclusion column was assessed by Dynamic Light 
Scattering (DLS). The quantification of peptide bound to liposomes was determined 
by bicinchoninic acid (BCA) assay, while phospholipid content was quantified by 
Wako phospholipid assay. The effects of the different types of liposomes on Aβ 
toxicity and viability of SHSY-5Y neuronal cells were examined by MTS assay, whereas 
effects on Aβ aggregation were determined by Thioflavin-T (Th-T) assay. In addition, 
a cell penetration assay was carried out in order to examine the ability of liposomes 
to penetrate into neuroblastoma SHSY-5Y cells. 
vii 
 
Results: Low concentrations of PINPs 0.1 μM inhibited Aβ aggregation and toxicity in 
vitro. MAL-PEG liposomes and PINPs were able to penetrate into neuroblastoma 
SHSY-5Y cells and were also more stable than simple liposomes. Stability means the 
ability of liposomes to keep their size and their shape stable for long time. In 
addition, the three types of liposomes were not toxic towards SHSY-5Y 
neuroblastoma cells. Cytotoxicity is the quality of being toxic to cells. So, none of the 
three types of our liposomes showed any negative effect on the viability towards 
SHSY-5Y neuroblastoma cells. 
Conclusion: NLPs are an ideal carrier for our aggregation inhibitors because they 
affect Aβ aggregation and toxicity at low doses, and according to other data 
generated by our group, can cross the Blood Brain Barrier (BBB).  
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CHAPTER ONE - INTRODUCTION 
1.1 Diseases of the brain 
Each living organism in order to function properly needs healthy cells to 
correctly perform all of their required functions. Cells are the smallest units of life 
and their function is based on thousands of different proteins (Dobson, 1999). If a 
particular protein is disrupted, the three dimensional structure can become 
misfolded, and this can lead to the aggregation of that protein. Many previous 
studies and observations support the idea that the aggregation of misfolded proteins 
in various organs and tissues is directly associated with numerous human systemic 
and neurodegenerative diseases, the latter being driven by the accumulation of 
misfolded protein fibrils in the brain. This group of brain diseases includes: 
Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia with Lewy bodies (DLB), 
Creutzfeldt-Jacob disease (CJD), motor neuron disease (MND), Huntington’s disease 
(HD) and frontotemporal dementia (FTD) (Soto, 2003). All are due to the 
degeneration of a specific population of nerve cells in the brain and spinal cord 
leading to corresponding clinical features of the disease. 
 The majority of the neurodegenerative diseases noted above are age related 
and are often caused by a combination of both environmental and genetic factors. 
Furthermore, all are incurable diseases (Martin, 1999; Soto, 2003). This is a particular 
problem in the case of AD which is recognized as the most common 
neurodegenerative disease caused by the uncontrolled accumulation of misfolded 
proteins in the brain. Consequently, scientists are trying to understand the causes of 
this disease and how to diagnose and treat it more efficiently, including development 
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of drugs which limit the accumulation of misfolded proteins in the brain. In the next 
sections of the introduction I will consider more about AD (risks factors, diagnostic 
methods, current treatments) and generally how PINPs might function as an efficient 
drug for this disease. 
 
1.2 Alzheimer’s disease - Overview of pathology 
At the beginning of 19th century (1906), the German psychiatrist Alois 
Alzheimer described the first recognized case of AD, in a fifty one year old female 
patient called Auguste Deter, reviewed by (Moller and Graeber, 1998). She suffered 
from unstable behavior (usually aggressive behavior), disorientation and language 
problems. After the death of this patient, Alois Alzheimer brought to light the 
presence of two lesions in her brain: (a) senile plaques, now known to contain paired 
helical filaments amyloid β-protein (Aβ) and (b) neurofibrillary tangles, now known to 
be composed of hyperphosphorylated, aggregated Tau protein (figure 1.1) (Haass and 
Selkoe, 2007). In the early stages of AD the most common symptom is difficulty in 
remembering recent events, known as short term memory loss (memory 












Figure 1.1: Comparison of normal, healthy neuronal cells/brain and those in AD. This illustration 
shows a normal brain with healthy neuronal cells (healthy neurons and absence of amyloid plaques) 
and an AD brain with senile amyloid plaques (brown) and neurofibrillary tangles (purple unhealthy 
cells). The photograph of the brain with AD shows shrinkage and loss of cerebrocortical grey matter 
together with the enlargement of the fluid-filled ventricles (Bird, 2008). 
Since this first recognised case of AD described by Alois Alzheimer, many 
scientists have tried to understand the cause of this neurodegenerative disorder and 
how to develop a method to cure it. AD is the most common neurodegenerative 
disease and affects people of both genders mainly over the age of 65 years (Blennow 
et al., 2006).  It is important to note that, due to the development and improvement 
of the sector of medicine and technology over the years, the average of human life 
span is increasing continuously and as a result more people will have a higher risk of 
developing this disease (figure 1.2). According to Ferri et al. (2005) in the year 2000 
around 24 million people worldwide were affected by AD and this number is 
expected to approximately double every 20 years, to 48 million in 2020 and 96 









Figure 1.2: The graph shows the number of cases of AD in males and females as a function of age. It 
is observed that as age increases, the risk of developing AD increases exponentially (Nussbaum and 
Ellis 2003). 
  
1.3 Clinical features of Alzheimer’s disease 
The clinical features which characterize the disease are memory problems, 
aphasia (difficulty with speech and loss of ability to understand speech), apraxia 
(inability to make voluntary movements) and agnosia (difficulty with recognition of 
objects). Additionally, people with AD often present with aggressive behavior, sleep 
disturbances, mental uneasiness, impaired judgment and delusions (Blennow et al., 
2006). Underlying these clinical features of AD, there are various neuropathological 
changes such as:  decrease in brain volume, gliosis, enlargement of ventricles within 
the brain, extreme shrinkage of the hippocampus and parts of the cerebral cortex, 
loss of the synapses which are necessary for communication between nerves cells, an 
inflammatory response, and extensive and early oxidative damage, as well as 
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changes in the acetylcholine transmitter system in the brain due to loss of cholinergic 
neurons. It is now realized that some of these changes start to occur 2-3 decades 
before any overt clinical features are manifested (Davies et al., 1988). The first 
symptoms of AD probably emerge when the amyloid plaque and the neurofibrillary 
tangle burden accumulate above a certain critical threshold, which may vary 
between individuals. An early stage of the disease is called Mild Cognitive 
Impairment (MCI), where there are mild but noticeable changes in cognitive function 
(Peterson, 2004). Some people with MCI will progress to develop full-blown AD. AD 
itself is divided into three distinct stages: (a) early diagnosis, where some cognitive 
symptoms appear along with mood swings and personality changes, (b) mild-
moderate, which is defined by the appearance of some behavioral problems, in 
conjunction with memory impairment such that patients are unable to learn and 
recall new information. The third stage (c) is the severe-late stage, which is defined 
by advanced symptoms of the disease such as complete loss of memory, inability to  
eat or swallow, and partial loss of motor skills, which finally leads to death (Blennow 
et al., 2006). The cause of sporadic disease is presumably due to a mix of genetic and 
environmental factors, while a small percentage (5%) of cases are caused by gene 







1.4 The genetics of Alzheimer’s disease 
 It is important to note that AD is divided into two forms, the inherited early-
onset form and the sporadic late-onset form (Allsop and Mayer, 2014). The inherited 
form of the disease generally affects individuals younger than 60 years (32-59 years) 
and usually progresses more rapidly than late-onset AD. The mutations responsible 
for familial AD are found in genes encoding the amyloid precursor protein (APP), 
presenilin 1 (PS1) and presenilin 2 (PS2) (Mattson 2010; Sherrington et al., 1995).  
The first familial cases of AD discovered were caused by mutations in the APP gene 
on chromosome 21, which result in an increase in the levels of Aβ in general or Aβ42 
in particular (more information about Aβ below). Currently 25 pathogenic APP 
mutations are associated with FAD. In Down’s syndrome, trisomy of chromosome 21 
leads to overexpression of the APP gene product which leads to overproduction of 
amyloid-β (Selkoe, 2001). Later it was discovered that the most common reason for 
familial AD is due to mutations in the highly homologous presenilin 1 (PSEN1) and 
presenilin 2 (PSEN2) genes, which are actually components of the γ-secretase 
enzyme complex and also lead to an increase in the levels of Aβ42 peptide. 
Furthermore, in 1993 two groups of scientists pointed out an association 
between of Apolipoprotein E (APOE) ε4 and AD and it was revealed that the presence 
of APOE ε4 increases the risk of developing the disease by three times in 
heterozygotes and by 15 times in homozygotes. APOE is a glycoprotein which is a 
constituent of lipoproteins and is composed of ~ 300 amino acids. Its role is related 
to the transport of cholesterol to the cells (Pfrieger, 2003; Wernette-Hammond et al., 
1989). APOE ε4 constitutes one of the alleles of APOE. There are three alleles (ε2, ε3, 
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ε4) resulting in 3 (E2, E3, E4) different APOE isoforms which differ only by one or two 
amino acid substitutions at residues 112 or 158 (Mahley et al., 2006). The ε4 allele of 
the APOE gene was found to be an important genetic risk factor for late-onset AD 
(Namba et al., 1991; Wisniewski and Frangione, 1992), with risk increasing for people 
with one and two ε4 alleles (Corder et al., 1993). 
Table 1.1: The genes involved in familial AD. The table indicates the different chromosomes and 
genes which cause an increase in the levels of Aβ42 peptide and are consequently linked to AD. 
In addition, triggering receptor expressed on myeloid cells 2 (TREM2) has been 
identified as a gene which is associated with late-onset sporadic AD and increases 
the risk of developing the disease to a similar extent as APOE ε4. TREM2 is a 
transmembrane glycoprotein and is primarily expressed by microglia of the central 
nervous system (CNS) (Bouchon et al., 2000; Guerreiro et al., 2013; Sessa et al., 
2004). The expression of TREM2 occurs simultaneously with the formation of senile 
Chromosome Gene product Inheritance Phenotype 
14 Presenilin-1 Autosomal dominant Early onset AD - PS 
mutation increases the 
levels of Aβ42 peptide. 
1 Presenilin-2 Autosomal dominant Early onset AD - PS 
mutation increases the 
levels of Aβ42 peptide. 
21 APP Autosomal dominant Early onset AD - APP 
mutations increases the 
levels of Aβ in total or 
Aβ42 in particular. 
21 APP Trisomy 21 Down’s syndrome. 




plaques. In addition the expression of TREM2 affects the function of microglia by 
stimulating them to induce proliferation CD4+ T cells and promote the secretion of 
tumor necrosis factor and CCL2 into the extracellular milieu (Melchior et al., 2010). 
 
1.5 Risk factors 
The most obvious and unquestionable risk factor for AD is ageing, most likely 
related to ageing of the brain. Apart from ageing, various epidemiological studies, 
support the fact that a decreased brain reserve (small size brain, poor educational 
achievement) along with reduced mental and physical activity in later life constitute 
important risk factors for developing AD (Mayeux, 2003; Mortimer et al., 2003). In 
addition, brain injury (head trauma) can also apparently cause AD by precipitating 
formation of amyloid plaques and neurofibrillary tangles or by reducing the brain 
reserve (Jellinger, 2004). Additionally, some other risks factors include high levels of 
cholesterol, high blood pressure, atherosclerosis, smoking and diabetes, which can 
arise due to an unhealthy lifestyle.  Diabetes mellitus type 2 (DM2) also constitutes a 
major risk factor for the development of early-onset AD. All of these risks factors are 
directly associated with vascular disease which can also cause AD by accelerating 
plaque and the tangle formation (Mayeux, 2003; Biessels et al., 2006; Haan, 2006). 
Consequently, many of the environmental risk factors can be limited and can be 
controlled by engaging in a healthy lifestyle. 
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1.6 Alzheimer’s disease and amyloidosis 
Amyloidosis is a general term used to describe diseases which are caused by 
the deposition of insoluble amyloid fibrils in various tissues and organs of the body 
(Allsop and Mayes, 2014). It is important to note that all amyloid deposits share 
common physical, histological and structural features such as: reactivity to thioflavin 
and Congo red stains, high levels of insolubility, and presence of 7-10 nm diameter 
fibrils with a rope-like structure (Allsop and Mayes, 2014). The formation of amyloid 
fibrils constitutes a big challenge in dealing with AD since they have the ability to 
resist proteolytic degradation and can sometimes accumulate in vast quantities 
which can cause physical damage and precipitate apoptosis of cells, leading to organ 
failure, and this can ultimately prove fatal.  It is noteworthy that amyloid is also often 
found in healthy individuals in controlled quantities in most major tissues and organs 
without causing any overt pathological damage. Contrariwise, the accumulation and 
the high concentration of amyloid fibrils in disease states are pathogenic and 
damaging to cells and tissues. Many of the brain diseases can be characterized as 
amyloidoses and the most common type of amyloidosis is AD (Wisniewski et al., 
1997). There are more than 30 different types of proteins which are responsible for 
the formation of amyloid but regardless of the type of the protein from which 
amyloid is formed they all share the common physical, histological and 
ultrastructural properties mentioned above (Ghiso and Frangione, 2002). 
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The formation of amyloid fibrils follows a specific pathway whereby its native 
form of the protein becomes misfolded and starts to aggregate. This can be 
illustrated by the prion protein (PrP) where the native form is predominantly α-helix/ 
random coil but can become misfolded into the “scrapie” form (PrPSc) which is 
infectious and rich in β-sheet structure (figure 1.3) (Gosal et al., 2006; Soto, 2003; 






Figure 1.3: The structure of protein when misfolded into β-sheets. Illustration shows the three 
dimensional shape and structure of the two types of prion protein, PrPc = cellular form (non-infectious) 
and PrPSc = ‘scrapie’ form (infectious). The PrPSc form has a large increase in β-sheet content. 
The conversion of the native protein into the misfolded form is due to various 
changes in structure of the protein, creating an unstable intermediate misfolded 
protein which due to hydrophobic interactions with other similar protein molecules 
leads to the formation of more stable β-sheet oligomers. Next, the β-sheet oligomers 
grow further to form protofibrils, which finally twist around each other to form 
amyloid fibrils (Soto, 2003). The amyloidoses are divided in two broad categories: 
systemic (widespread throughout the body) or local where the amyloid is restricted 
only to a specific organ (such as heart, pancreas, brain, etc.). AD is classified as a local 
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amyloidosis due to accumulation of β-amyloid protein selectively in the brain, 
following its release by proteolytic cleavage from the amyloid precursor protein 
(APP).  
 
1.7 Formation of Aβ from the amyloid precursor protein (APP) 
The amyloid precursor protein (APP) is an integral transmembrane glycoprotein 
and is expressed in many tissues and organs, including neuronal cells. APP belongs to 
a family of proteins which comprises APP along with the amyloid precursor-like 
proteins (APLP1 and APLP2) in animals (O’Brien and Wong, 2011). APP is processed 
by proteolysis to generate Aβ. Alternate splicing of APP can occur and result in the 
generation of eight different length isoforms of the protein, but three of these are 
the most common. The first isoform is composed of 770 amino acids, the second is 
composed of 751, and both are expressed in multiple tissues and organs, while the 
smallest common isoform is composed of 695 amino acids and is mainly 
concentrated in the CNS, specifically in the brain (Allsop and Mayes, 2014; Bayer et 
al., 1999).  
The amyloid-β peptide is composed of 39-43 amino acids and is found even in 
healthy people, but in the case of AD it becomes misfolded and aggregates to form 
amyloid fibrils which may be toxic for nerve cells (Austen et al., 2008). Aβ exists in 
two major forms: Aβ42 and Aβ40. Both spontaneously aggregate in vitro into 
amyloid fibrils but Aβ42 does this more rapidly than Aβ40, and so is more 
pathogenic. APP is partially embedded in the plasma membrane of the cell, while a 
large part of the protein protrudes from the surface. The Aβ section of APP is also 
12 
 
partially embedded in the plasma membrane with the larger part (28 amino acids) of 
the domain outside of the transmembrane region and a smaller part (12-14 residues) 
embedded in the interior of the membrane (Blennow et al., 2006). 
According to the action of specific proteases called secretases, APP is cleaved 
at three distinct sites, producing two alternative pathways, one of which is none 
pathogenic, while the other releases Aβ, so potentially leading to AD (see figure 1.4). 
The three secretases which can cleave APP are: α-secretase, β-secretase and γ-
secretase (Thornton et al., 2006). The pathogenic pathway resulting in production of 
amyloid-β is also called the “amyloidogenic” pathway while the normal cleavage of 
APP does not produce Aβ and is called non-amyloidogenic pathway. In the case of 
the non-amyloidogenic pathway, the cleavage of APP is initiated by α-secretase 
cleavage between residues 16-17 of the Aβ domain, and then γ-secretase follows to 
generate a nonpathogenic peptide called p3.  
13 
 
Figure 1.4: The Amyloid cascade hypothesis. This illustration shows how the cleavage of APP by the 







1.8 Amyloid cascade hypothesis 
Despite many years of research the underlying cause of AD remains unclear 
and is still under debate (Dong et al., 2012). Among the various hypotheses for the 
cause of AD, the one which prevails today and is the most accepted globally is the 
“amyloid cascade” hypothesis (Bachman et al., 2013).  
According to this hypothesis, the main event for the pathogenesis of this 
neurodegenerative disorder is disruption of the control mechanisms related to 
production of Aβ and the ability to clear this toxic peptide from the brain. An 
imbalance in this system in favour of brain accumulation results in formation of 
amyloid fibrils which are potentially toxic to nerve cells (Verdile et al., 2004; Glenner 
and Wong 1984) and precipitate a cascade of events, including tangle formation, 
which culminates in neural cell damage/death. In the case of inherited diseases 
mutations in APP, PS1, PS2 genes result in overproduction of Aβ, while in the case of 
sporadic disease, there is likely to be a problem with Aβ clearance (Blennow et al., 
2006). In a more recent “variant” of this hypothesis, toxic oligomers of Aβ inhibit 
long-term potentiation (LTP) and disable synaptic capacity, resulting in the loss of 
communication between nerve cells and ultimately in their death (Blennow et al., 
2006; Hardy and Selkoe 2002).  
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Figure 1.5: The diagram shows the formation of amyloid fibrils from monomeric Aβ. For the 
formation of mature fibrils as it shown in the diagram above the monomers follow two pathways. The 
“ON” pathway which the monomers gradually assemble to oligomer, and then to nucleus and finally to 
mature fibrils while in the case of the “OFF” pathway the monomers assemble directly to nucleus and 
then to mature fibril. In both pathways, it is believed that the Aβ oligomers are more toxic than mature 
fibrils (Allsop and Mayes, 2014). 
 
According to the latter hypothesis the oligomers (dimers, trimers) are 
considered as a potential drug target and are believed to be more toxic than Aβ 
fibrils. The amyloid oligomers or Aβ-Derived Diffusible Ligands (ADDLs) are small, 
soluble and diffusible toxic entities which can block LTP and affect memory process 







1.9 Current diagnosis of AD 
The early diagnosis of AD could lead to early intervention and so play an 
important role in the treatment of the disease. Nowadays, there are a variety of 
methods which are used for diagnosis, but a definitive diagnosis of AD can still only 
be made after death when the presence of large numbers of senile plaques and 
neurofibrillary tangles can be verified (Van der Zee et al., 2008). A correct diagnostic 
work up is usually based on the medical history of the patient, memory tests and 
rating scales (e.g. MMSE) which confirm genuine cognitive impairment, and a 
neuropsychiatric examination. These above medical examinations identify any 
symptoms at the early stage of the disease, and, importantly can exclude other 
possible causes of dementia. In addition, two more useful diagnostic methods which 
are used to exclude other causes of dementia (e.g. brain tumor, stroke, etc.) and also 
reveal cerebral atrophy (an indicator of neurodegeneration) and simultaneously 
detect AD are Magnetic Resonance Imaging (MRI) which detects hippocampal and 
cerebral atrophy and Computerized Tomography (CT) (Blennow et al., 2006). Other 
clinical diagnostic methods which can aid in the diagnosis of AD are: cerebrospinal 
fluid (CSF) levels of amyloid-β (especially Aβ42) and Τau protein, fluorodeoxyglucose 
positron emission tomography (FDG-PET) to detect a decrease in the metabolic rate 
of glucose utilization and Positron Emission Tomography (PET) which can be used to 
quantity Aβ deposition in the living brain (Apostolova et al., 2010). Pittsburgh 
compound B (PiB) is a labelled compound which is used in PET imaging to bind to 
amyloid fibrils in the living brain (Forsberg et al., 2008). One of the most important 
aims in diagnosis of AD is early detection of the disease, because the destruction of 
nerves cells probably begins many years before the appearance of AD symptoms. 
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This can be avoided if the patient is diagnosed early. Irreversible damage to the brain 
and generally early diagnosis should lead to a more effective treatment, especially if 
there is an appropriate, disease-modifying therapy available (Nazem and Mansoori 
2008; Mortimer et al., 2005).  
 
1.10 Current symptomatic treatment of AD 
Even today, the effective treatment of AD remains a goal that has not been 
accomplished. The current treatments for AD are still only used for temporary 
mitigation of symptoms. The cholinergic hypothesis of AD comes from some of the 
first studies showing that the cholinergic neurons which protrude from the low areas 
of the brain up to the higher areas, and are involved in memory, are selectively lost 
early in the course of AD. In other words, the loss of cholinergic function is directly 
associated with the loss of short term memory. This finding led scientists to look for 
alternative ways to increase acetylcholine, or protect these neurons, and initially 
resulted in the development of Aricept as an effective acetylcholinesterase (Ache) 
inhibitor (Terry and Buccafusco, 2003). 
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Figure 1.6: "Cholinergic hypothesis" of AD. The illustration on the left shows the mechanism of how 
AChe inhibitors block the breakdown of ACh while the picture on the right shows the chemical reaction 
(the reactants and products) for the formation and the breakdown of ACh. 
Acetylcholinesterase (AChe) inhibitors have the ability to block the breakdown of 
ACh at the synapse, in order to boost cholinergic transmission. These types of drugs, 
however, are only symptomatic treatments which delay cognitive decline (for 6-12 
months) in some (approximately 50%) patients with AD (Blennow et al., 2006). 
Galantamine (Reminyl®), Donepezil-HCl (Aricept®) and Rivastigmine (Exelon®) are the 
3 acetylcholinesterase inhibitor drugs currently approved by NICE for mild-moderate 
AD. 
These drugs have little effect in severe, advanced cases of AD and are almost 
certainly not targeted at the underlying cause of disease and so their effects are 
expected to be purely symptomatic.  In addition, the AChe inhibitors also have some 
side-effects such as nausea, vomiting, diarrhea, and some of them can cause liver 
toxicity. However, gastrointestinal symptoms can easily be controlled by starting the 
treatment with a low dose, and the drugs must be consumed with food to delay the 
absorption of the drug (Blennow et al., 2006).  
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Memantine is a differently acting drug which is used to modulate a healthy 
balance in the levels of glutamate neurotransmission in the brain. In normal 
conditions, glutamate and its interaction with the N-methyl-D-aspartate (NMDA) 
receptor are involved with learning and memory. On the other hand, in abnormal 
conditions such as AD, an increase of glutamate concentration can cause decreased 
function of NMDA receptors and be fatal for nerve cells. Memantine is a non-
competitive antagonist of the NMDA receptor (Areosa et al., 2005) and is the only 
drug currently approved by NICE for more advanced AD, but again has only a modest 
effect on the disease. In addition to the AChe inhibitors there are also some 
alternative therapeutic approaches which have been under development for AD. 
Inhibition of β-secretase or γ-secretase and stimulation of α-secretase 
The secretases play important role in the proteolysis of APP and generation of 
Aβ which then aggregates into toxic oligomers. More specifically, β-secretase and γ-
secretase are the two secretases which are responsible for the production of Aβ, and 
so inhibition of either of these two secretases could provide a viable therapy for AD. 
β-secretase activity is due to an integral membrane aspartyl protease called BACE1, 
but development of BACE1 inhibitors has proved to be difficult  because of inherent 
medicinal chemistry problems (the enzyme has a large binding pocket). Regarding γ-
secretase, this enzyme also cleaves notch and so inhibitors of this enzyme will also 
interfere with notch processing. Notch receptor is single-pass transmembrane 
receptor protein. Notch signaling has the ability to proliferate signaling during 
neurogenesis (Xiao, et al., 2009). On the other hand, the action of α-secretase 
prevents the formation of Aβ, although it also cleaves several important growth 
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factor precursors at the membrane. This enzyme has been identified as a 
metalloprotease, but it is easier to develop drugs which inhibit rather than stimulate 
enzyme activity. Moreover, stimulation of α-secretase could have negative 
consequences due to a decrease in the levels of cholesterol, and effects on activation 
of G-protein-coupled receptors (Grandy, 2005; Petit et al., 2001).  
Aβ immunotherapy 
In the field of immunotherapy, scientists have developed an AD vaccine 
(AN1792) in the form of aggregated Aβ42 or anti-Aβ antibodies which can clear the 
amyloid plaques from the brain (Fu et al., 2010). Unfortunately, trials of this type of 
vaccine were initially stopped during phase III because some patients developed 
severe aseptic encephalitis and brain inflammation (Fu et al., 2010; Blennow et al., 
2006). There are two types of immunotherapy: (a) active and (b) passive 
immunotherapy. In the case of active immunotherapy attenuated Aβ or synthetic Aβ 
was administrated to patients in order to stimulate cellular and humoral immune 
responses in the host and to generate anti-Aβ antibodies, while in passive 
immunotherapy, Aβ-specific antibodies are directly injected into the patient (Fu et 
al., 2010). AN1792 vaccine was an example of active immunotherapy. Treatment of 
AD has also involved use of passive immunotherapies such as: Lilly’s solanezumab, 
Pfizer’s bapineuzumab and Roche’s Gantenerumab, which substantially reduced Aβ. 
Solanezumab is a humanized monoclonal antibody against Aβ which failed against its 
target, although it did show 30% efficacy in patients with mild disease. NIH taking 
this further with a 1,000-patient study that is expected to yield results in 2018.   
Bapineuzumab was stopped in clinical phase III trials in 2014 because it did not has 
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any improvement in the clinical outcomes of AD, while Gantenerumab was stopped 
in phase III in 2014 in the people with mild cognitive impairment (MCI). 
Inhibition of TAU protein 
Another possible therapy is to inhibit formation of the neurofibrillary tangles 
which are created from the aggregation of Tau protein. Neurofibrillary tangles are 
dense rays of filaments that form inside the nerve cells. They are likely to be 
damaging to nerve cells, for example by inhibiting axonal transport (Mangialasche et 
al., 2010). However, inhibitors of Tau aggregation have produced disappointed 
results, with some drugs such as valproate and lithium giving side-effects, although 
others such as methylioninium chloride have produced better results (Mangialasche 
et al., 2010; Brodaty et al., 2011). Methylioninium chloride is also called methylene 
blue or “Rember” and is one of the most promising drugs for inhibition of Tau protein 
aggregation. According to a recent study, Wischik and coworkers have postulated 
that the aggregation of Tau protein inside the nerve cells leads more directly to the 
development of dementia (Wischik et al., 2008). In 2008, Wischik and coworkers 
reported that methylioninium chloride phase 2 clinical trials in AD gave promising 
results, with positive expectations for the future (Wischik et al., 2008).  However, 
methylioninium chloride is likely to have multiple effects, for example it also has an 
effect on mitochondrial function by enhancing key mitochondrial biochemical 
pathways. Here, methylioninium chloride is able to limit the inhibition and increase 





Aβ fibrillization inhibitors 
The aim of these inhibitors is to prevent the conformational change of Aβ to β-
sheet structures, and finally to fibrilization of Aβ, by intervening in interactions 
between Aβ - Aβ or Aβ - ApoE. One of the drugs which has been shown to reduce the 
formation of Aβ fibrils is NC-531 which interferes with the association between 
glycosaminoglycans and Aβ. This drug is still in phase III clinical trials. Another drug 
which was used for the inhibition of Aβ fibrils is the metal chelator clioquinol (PBT-1), 
which initially showed positive results, but after phase II clinical trials was stopped 
due to toxic impurities (a di-iodo form of clioquinol). A previous version of drug 
which called PBT-2 and does not contain any toxic compounds, such as iodine, is 
currently undergoing clinical trials (Geerts, 2004; Cherny et al., 2000; Ritchie et al., 
2003). 
Inhibition of Aβ oligomer formation 
The development of small molecules or peptide inhibitors which have the 
potential to bind to Aβ and prevent the formation of toxic Aβ oligomers is a 
promising strategy (Parthsarathy et al., 2013) which could delay or even halt the 
progression of AD, if given at an early stage during the course of the disease.  
 
1.11 The evolution of peptide inhibitors against the β-amyloid oligomerization 
We and others have been working on development of peptides which have the 
potential to bind to Aβ and inhibit the formation of early amyloid-β oligomers. A 
variety of different types of Aβ aggregation inhibitors have been described in the 
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literature but most of them are unsuitable for clinical development, and so few of 
them have progressed to animal testing and even fewer to human clinical trials 
(Taylor et al., 2010; Howlett, 2011; Karran et al., 2011; Parthsarathy et al., 2013; Ma 
et al., 2009). Many of the peptide-based inhibitors are based on the finding that the 
internal sequence KLVFF (amino acids 16-20) is involved in binding interactions 
between Aβ molecules (Tjernberg et al., 1996; Tjernberg et al., 1999). 
Initially, many of the attempts to develop aggregation inhibitors were based on 
inhibition of the late fibrillary form of Aβ rather than the early oligomeric assemblies. 
Soto and colleagues (Soto et al., 1996, Soto et al., 1998) developed “β-sheet breaker 
peptides” by adding proline residues into the binding region of the amyloid peptide, 
for destabilization of the β-sheet-rich structure which initiates aggregation (Adessi 
and Soto, 2002). The use of N-methylated peptides (or meptides) is an alternative 
approach, where the inhibitors has the ability to bind to the aggregating Aβ peptide 
via one face of the inhibitor but is unable to bind via the other (Kokkoni et al., 2006). 
Another different strategy was based on ten residues of the Aβ peptide sequence 
(specifically from residues 15-25 of the peptide) linked to an oligolysine disrupting 
element. Unfortunately, these types of peptide inhibitors proved to be unsuitable for 
further clinical development as they don’t completely inhibit the aggregation but 
cause a change in aggregation kinetics (Ghanta et al., 1996).  
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Figure 1.7: Peptide inhibitors of Aβ aggregation. This illustration indicates the structure and the 
sequence of amino acids of the two inhibitor generations: the normal peptide (OR2) and retro-inverso 
peptide (RI-OR2). In the case of RI-OR2 version all of the L-amino acids are replaced with D-amino acids 
and the sequence is reversed resulting in the generation of a peptide which has a similar 3D 
orientation but the backbone of the peptide is backwards. The red highlighted region on the amino 
acid sequence (16-20) indicates the binding site of the peptide inhibitor. The Arginine – Glycine termini 
were added to prevent self-aggregation of the peptide. 
In a more, recent study Austen et al. (2008) designed two peptide aggregation 
inhibitors having as their main sequence the central amino acid region of Aβ 
(residues 15-25 KLVFF) which is responsible for the binding association between Aβ 
peptides. The two peptide inhibitors were OR1 and OR2, and contained additional 
arginine (R) and glycine (G) residues on both ends of the molecule, in order to 
enhance solubility. The cationic arginine (R) was added to the peptide sequence 
through a simple Glycine (G) spacer, which prevents them from self-aggregating, 
while still allowing the interaction between the inhibitor peptides and amyloid-β 
molecules. The only difference between the two peptide inhibitors is that OR1 has an 
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amine group at the N-terminal end and a carboxyl group at the C-terminal end, while 
the OR2 inhibitor has an acetyl group on N terminal and amide on C.  
Both OR1 (H2N-RGKLVFFGR-COOH) and OR2 (H2N-RGKLVFFGR- NH2) had the 
ability to inhibit the formation of Aβ fibrils, but according to results obtained with 
different techniques such as Th-T assay, Transmission Electron Microscopy (TEM), 
ELISA assays and Congo red binding, OR2 was proven to be more effective than OR1 
because it had the greater potential to inhibit the formation of early Aβ oligomers 
(Taylor et al., 2010). On the other hand OR1 appeared to block formation of fibrils 
but not early Aβ oligomers. Consequently, further efforts were then focused on the 
OR2 inhibitor peptide. Despite the effective anti-aggregational properties of the OR2 
peptide inhibitor, there are many proteolytic sites on the inhibitor which would 
render it unsuitable as a drug candidate (Taylor et al., 2010; Austen et al., 2008). In 
order to overcome this limitation, a new “retro-inverso” version of the OR2 inhibitor 
peptide called RI-OR2 was developed (Chorev and Goodman 1995; Taylor et al., 
2010). Taylor and co-workers developed this new version of the peptide inhibitor by 
replacing the L-amino acids with D-amino acids and by reversing the bonds of the 
peptide.    
Even though RI-OR2 was still effective as an aggregation inhibitor it was not 
designed for penetration through the Blood Brain Barrier (BBB). Consequently, 
Parthsarathy and co-workers attached a retro-inverted version of the HIV (Human 
Immunodeficiency Virus) protein “TAT” (trans-activating transcriptional activator) 
onto RI-OR2 in order to increase its delivery into nerves cells, and also facilitate its 
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passage across the BBB. The newly formed version of the peptide was called RI-OR2-
TAT (Ac-rGffvlkGrrrrqrrkkrGy-NH₂) (Parthsarathy et al., 2013).  
Figure 1.8: The modification of peptide to enable brain penetration. This illustration shows the 
different functional regions of the peptide inhibitor RI-OR2-TAT and specifically the TAT transit 
sequence which was also retroinverted.  
 
1.12 Development of new therapies for AD 
1.12.1 Biological aspects for drug delivery in the Central Nervous System (CNS) 
The brain is one of the most sensitive systems of the human body and the 
presence of the BBB is necessary for the maintenance of its homeostasis (Masserini, 
2013). The anatomy in the capillaries of brain has evolved in such way as to prevent 
the passage of any toxic or unwanted molecules or chemicals which can harm the 
brain (Gabathuler, 2010). The BBB and the blood-cerebrospinal fluid barrier (B-CSFB) 
are the two types of barriers which coexist in the human organism and function 
simultaneously in order to separate the peripheral circulation from the CNS. 
Furthermore, in order to function properly, all of the biochemical processes of the 
nervous system, such as neurotransmission, the generation of new neurons, the 
development of new blood vessels, and other functions, require both barriers to be 
intact to keep in balance the chemical composition of the neuronal “milieu” (Spuch 
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and Navarro, 2011). The BBB has as a functional unit the cerebrovascular endothelial 
cells, the B-CSFB has as a functional unit the choroid plexus epithelium, and 
eventually the third barrier is the arachnoid epithelium (Neuwelt et al., 2008). 
 
1.12.2 Blood Brain Barrier (BBB) 
The BBB is composed of a complex of capillary endothelium, astrocytes, 
pericytes, and extracellular matrix and forms an effective security system for the 
brain. The presence of tight junctions among the endothelial cells makes the barrier 
impermeable for many substances found in the blood (Sandoval and Witt, 2008). The 
BBB is only permeable to certain molecules, ions and specific macromolecules such 
as nutrients which must enter the brain or exit from it as waste products. Based on a 
recent study, only the 2% of the small molecules with molecular weight smaller than 
500 Da in the blood are able to cross the barrier while all of the larger molecules in 
the blood, with molecular weight greater than 1 kD do not cross the BBB (Pardridge, 
2007). Figure 1.9 shows the possible ways by which a molecule or ion can pass 
through the BBB. However, the BBB also restricts the delivery of numerous drugs 
designed to prevent the treatment of many neurological diseases. Only a small 
number of drugs are able to cross the BBB and finally reach their target in the brain. 
To be able to do so these molecules require some special properties such as 
lipophilicity, a size smaller than ~50 Da, and evasion of the mechanism of active 
extrusion (Gabathuler, 2010). Consequently, due to the strict limitations to the 
permeability of different molecules and drugs from the blood circulation through the 
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BBB, some diseases which are related with the brain or the CNS are difficult or even 
impossible to diagnose and cure effectively.  
 
1.12.3 Blood–cerebrospinal fluid barrier (B-CSFB) 
The cerebral ventricles in the brain coexist with the choroid plexus which is a 
branched vascular tissue. The epithelial cells of the choroid plexus constitute the B-
CSFB which are joined together by tight junctions and control the permeability of 
different molecules and nutrients. In addition, on the surface of the epithelial cells 
are numerous villi which project from the cells and facilitate the secretion of 
cerebrospinal fluid (Spector and Johanson, 1989). 
Figure 1.9: Forms of passage of substances into the brain across the blood-brain barrier. This 
illustration shows five possible ways of passage of substances through the BBB accord to the nature of 
the substance. (A) Paracellular aqueous pathway, (B) transcellular pathway, (C) Through membrane 
proteins, (D) receptor-mediated transcytosis of macromolecules and (E) Adsorptive transcytosis 




1.12.4 Strategies for overcoming the Blood Brain Barrier 
CNS disorders constitute one of the main challenges for pharmaceutical 
companies and academic research teams due to their complexity, but also due to the 
presence of the BBB which prevents use of a wide spectrum of drugs. This especially 
applies to drugs directed at CNS diseases such as AD, PD and brain tumors. So the 
challenge for scientists is to discover strategies and construct drugs which have the 
potential to penetrate from the blood circulation system through the BBB. This has 




1.13.1 Nanomedicine for drug delivery in the CNS 
Nanotechnology can be defined as the science and engineering required for 
construction and manipulation of small particles on the nanometer scale (Burda et 
al., 2005). Nanotechnology and nanoparticles have started to be applied in a wide 
spectrum of scientific sectors in the last decade, such as the environmental sector, 
industrial and food agriculture sector, and of course in the field of biomedicine 
(Zaman et al., 2014). Interactions of artificial nanoparticles with biological systems 
with the aim of providing improved diagnosis and treatment of various diseases, is 
referred as “nanomedicine” which is a sub category of nanotechnology. In other 




Nowadays, the development of nanoparticles (NPs) plays very important role in 
the diagnosis and the treatment of many CNS diseases. A variety of different types of 
nanoparticles are used in medicine, such as: lipoplex, dendrimers, polymeric 
nanoparticles, polymeric micelles, nanotubes, silica nanoparticle, quantum dots, gold 
nanoparticles, magnetic nanoparticles, solid lipid nanoparticles, non-polymeric 
micelles and liposomes but the majority of them are composed of polymers and 
lipids, or a combination of both of these two (Wong et al., 2011). Consequently, the 
chemical composition of the nanoparticles constitutes an important element for 
their correct function. In addition, to their chemical composition, the size, shape and 
surface charge are also important parameters which can influence the ability of 
nanoparticles to pass through the BBB as well as determine their stability in the 
blood circulation system (Conti et al., 2006; Euliss et al., 2006). The rationale of using 
nanoparticles specifically for brain drug delivery is due to their unique features and 
advantages as biological carriers (Tassa et al., 2010). NPs can be defined as small, 
spherical and colloidal particles which have the ability to transfer a drug or 
therapeutic agent either inside of the nanoparticle, or by covalent attachment onto 
the surface of the nanoparticle. Some of the properties of these particles which make 
them ideal for the use in the field of medicine are: 
1. These particles can carry many diagnostic and therapeutic agents either by 
attaching them by covalent bonds on their surface or encapsulated them.  
2. The materials from which these nanoparticles are made can be biocompatible 
and biodegradable, such as lipids (nanoliposomes).  
3. Additionally, due to some unique features of nanoparticles such as chemical 
and biological stability, maintenance of NPs in the circulation system for a 
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long time after administration is feasible as well multiple ways of 
administration (oral, inhalational and paracentral), and so nanoparticles can 
be considered as ideal drug carriers for medical use (Pektar et al., 2011).  
4. Modification of the liposome surface with targeting agents such as 
polyethylene glycol (MAL-PEG) can lead to the creation of liposomes with 
high stability in the blood circulation and increase their lifespan.  
5. These PEGylated liposomes have “stealth properties” and as a result can hide 
from the immune system – protecting them for immune system clearance 
and helping to prevent adverse immune reactions. 
 
1.13.2 The generations of Nanoparticles (NPs) 
Based on many previous studies, scientists have managed to improve the 
nanoparticles to a great degree by modifying them, and learning more about their 
key characteristics such as size, structure, chemical composition and surface charge. 
Figure 1.10 summarizes the three generations of nanoparticles which have been 
applied in a variety of biological systems and experiments. Nanoparticles which 
belong to the first generation are made of innovative nanomaterials which were 
tested for their toxicity, cell uptake and biocompatibility (Kirchner, et al. 2005; 
Chithrani, et al., 2006). These experiments confirmed that nanoparticles of the first 
generation were unstable, and rapidly cleared from biological systems, which led 
scientists to design a new generation of nanoparticles (De Jong et al., 2008; 
Cherukuri et al., 2006). This second generation involved upgrading the chemical 
surface to improve stability, and their evolution was focused on two interconnected 
32 
 
concepts: (a) stealth, where liposomes are more stable and have a longer lifespan in 
the circulating system and (b) active targeting. An important molecule which was 
applied to the surface of the second generation of nanoparticles was the synthetic 
polymer poly-(ethylene glycol) (PEG). The incorporation of PEG molecule into 
liposomes led to the development of an innovative generation of more stable 
nanoparticles and more specifically nanoliposomes with great potential in the sector 
of medicine (Perrault et al., 2009; Zhang et al., 2009; Gref et al., 2000; Needham et 
al., 1992). However, the evolution of nanoparticles has continued with the 
development of a third generation with emphasis on how to design a much more 
sophisticated and responsive nano device which can deliver a therapeutic compound 
and act as an effective drug carrier in biological systems  (Albanese et al., 2012).   
Figure 1.10: The three generations of nanoparticles. The following diagram shows and compares the 
three generations of nanoparticles and their characteristics as well as and the fundamental bio-nano 




Despite all of the options which scientists had, to develop the ideal drug 
carrier, relatively simple nanoparticles made of liposomes (nanoliposomes)  
consisting of a single lipid bilayer (unilamellar) or many bilayers (multilamellar 
vesicles) have proved to be the most common and the most suitable type of 
nanoparticle for medical use.  
 
1.14 Liposomes design and function 
1.14.1 Liposomes general features 
Liposomes are small auto-assembly spherical vesicles which are mainly made 
from non-toxic lipids, and phospholipids, and were first described by haematologist 
Dr. Alec Bangham in the early 1960s (Dua et al., 2012). Liposomes have been widely 
used as delivery systems. Their size usually varies from a few nanometers (~20 nm) 
to several micrometers (~5 μm) but the ideal size for medical use is in the range 50 – 
450 nm (Etheridge et al., 2013). The most common materials which are used for the 
creation of liposomes are biocompatible and biodegradable lipids such as 
sphingomyelin, phosphoglycerides and phosphatidylcholine, and two or more lipids 
can be combined together in a mixture. Phospholipids are amphipathic molecules 
which have hydrophobic and hydrophilic properties (two hydrophobic tail made of 
hydrocarbon chains and a hydrophilic head which consisted by a phosphate group). 
For the creation of a liposome mixture, the lipids usually are dissolved in an organic 
solvent (e.g. chloroform) and then, the evaporation of lipid mixture follows to obtain 
a lipid film. Then, when the dry lipid film comes in contact with water, it 
spontaneously forms spherical vesicles, separating the inner space from the outer 
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(Vemuri and Rhodes, 1995; Vuillemard, 1991; Gabizon et al., 1998; Akbarzadeh et al., 
2013). The hydrophobic and hydrophilic properties of the lipids determine the 
spherical shape of liposomes, in which an aqueous volume is encapsulated in the 
central core of each liposome.  The chemical composition of liposomes is obviously 
an important factor for their correct function, and in addition to standard 
phospholipids, the insertion of cholesterol can improve the structural characteristics 
of the membrane.  
The presence of cholesterol in the membrane of liposomes is very important 
because it maintains the stability of the membranes in vivo and in vitro, and also 
decreases their permeability (Masserini, 2013; Lee et al., 2005). This is mainly due to 
the hydrophobic properties of cholesterol, based on its molecular structure with the 
four hydrocarbon rings, and as a result it has a tendency to interact with the central 
region of the membrane. Specifically when cholesterol reacts with unsaturated lipids 
which form kink in the chain, it is able to cover the space and so create a more 
stable, and rigid membrane by decreasing the flexibility of surrounding lipid chains. 
Cholesterol molecule in membranes is located parallel with phospholipids and the 
hydroxyl group interacts with the nearby phospholipid head groups (see figure 1.11) 
(Bozzuto and Molinari 2015). Consequently, cholesterol is considered an important 










Figure 1.11: Cholesterol disrupts the tight packing of the fatty acids. The illustration shows the 
orientation of cholesterol with sphingomyelin in membranes to the fatty acid chains and also the 
hydroxyl group of cholesterol (orange) interacts with the head group (red) of sphingomyelin. 
There are four classical methods which are used for the production of 
liposomes: Bangham method (hydration of lipid film), Reverse-Phase Evaporation 
(REV) technique, solvent (ether or ethanol) injection technique and detergent 
dialysis. Selection of the preparation method depends on several factors such as: the 
physicochemical characteristics of lipids, the toxicity of the loaded component, the 
cost of the whole method, and the size of liposome. Nevertheless, the most common 
technique is the Bangham method.  The production of the liposomes is followed by a 
freeze and thaw process, sonication, and finally the extrusion of the liposomes 
through a membrane in order to generate liposomes with controlled sizes (Dua et al., 
2012; Wagner and Vorauer-Uhl 2011; Bangham et al., 1965). 
1.14.2 Classification of liposomes 
In addition to their composition, liposomes are also classified based on their 
size and the number of bilayers (lamellarity) which are formed during their 
preparation. The size of liposomes plays a crucial role in determining whether they 
can pass through the blood vessel walls to target the lesions in cancer for example or 
pass through the BBB (in the case of brain diseases such as AD). Consequently, the 
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size of liposomes constitutes an important factor which can affect the success of the 
nanocarrier. Based on previous studies, scientists have found that liposomes of 
around 100-140 nm present some advantages, such as avoiding the interaction with 
plasma proteins, and evading the reticuloendothelial system (RES), which contribute 
to a longer half-life in the blood circulation (Fanciullino and Ciccolini 2009). On the 
other hand, PEGylated liposomes larger than 100 nm in diameter have a shorter half-
life because they are less able to evade the reticuloendothelial system. In a previous 
study which was carried out in order to test the time for the clearance of PEGylated 
liposomes of the same composition, it was found that those with 250 nm size were 
removed from the circulation more than twice as fast as liposomes 100 nm size 
(Woodle et al., 1992). However, smaller liposomes in the region of ~100 nm have a 
limited drug-storage capacity compared with larger sized liposomes (Allen, 1995). 
With regard to the number of bilayers, liposomes belong in two main 
categories: (a) multilamellar vesicles (MLV) and (b) unilamellar vesicles. Multilamellar 
vesicles range from 100 nm upwards and can reach a diameter of a few μm with 
many bilayers formed by the incorporation of many unilamellar liposomes inside one 
another to form an onion-like structure, while in unilamellar vesicles, the liposome 
has only one bilayer a with a diameter of 0.25 nm – 400 nm and they can encapsulate 
hydrophilic drugs. In addition, unilamellar vesicles can also be divided into two 
subcategories as follows: (i) Large Unilamellar Vesicles (LUV) with a diameter larger 
than 100 nm and (ii) Small Unilamellar Vesicles (SUV) with diameter about 20 nm up 









Figure 1.12: Modified illustration indicates the structure of two types of simple liposomes based on 
the number of layers. The (A) illustration represents a multilamellar vesicle which has three layers 
while the illustration (B) represents a unilamellar vesicle with a single layer. With both types of 
liposomes, during their formation, an aqueous volume is encapsulated in the central core. The 
hydrophilic heads of lipids interact with water while the hydrophobic tails avoid the interactions with 
water (Patil and Jadhav, 2014). 
 
1.14.3 Stealth liposomes and conventional liposomes 
 It is important to note that the majority of artificial liposomes are composed of 
the same lipids as those found in the cell membrane, and so they constitute a 
familiar and friendly environment for transfer of any agent into the cell (Huang et al., 
2014). Liposomes are therefore a harmless “invader” for the human body. 
Nevertheless, liposomes can be detected by the mononuclear phagocytic system 
(MPS) and cleared during blood circulation, creating some issues with their stability 
(Akbarzadeh et al., 2013; Maruyama et al., 1992).  
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As referred to above, the evolution of nanoparticles has solved some of these 
problems, one of these being their limited stability in vivo. Combining several 
methods, scientists have managed to overcome some of the limitations of liposomes 
by using coated liposomes (e.g. with chitin derivatives) and mainly by PEGylation of 
liposomes (attachment of polyethylene glycol molecules on the surface of the 
liposomes) (Shaheen et al., 2006). These are defined as “stealth liposomes” because, 
with PEGylation, liposomes are able to evade the immune system by decreasing their 
clearance from MPS so increasing their half-life in vivo (Bedu-Addo et al., 1996; 
Korgel et al., 1998; Drummond et al., 1999).  
 
1.14.4 Attachment of targeting peptides on the surface of liposomes - Peptide 
Inhibitor Nanoparticles (PINPs) 
The development of “stealth liposomes” has provided many prospects for the 
treatment of various diseases in the future, and they act as targeted bioactive 
molecules. There are several methods for the conjugation of targeting peptides, 
antibodies, proteins or drugs on the surface of liposomes, but for the design of 
targeted vesicles there are two main approaches (a) the attachment of the targeted 
ligand onto the surface of the liposome can be done during the preparation of the 
liposomes, or (b) the ligand can be conjugated onto the surface of the liposomes 
after their preparation, by covalent bonding.  The most common type of ligand 
conjugation on the surface of liposomes is carried out by ligands which contain 
molecules with a thiol group to react with maleimide or bromoacetyl anchors, 
forming two types of bonds (thioether or disulfide bonds) (Schuber et al., 2007; 
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Barbet et al., 1981). In addition, another common type of conjugation of a ligand on 
the surface of vesicles is where the ligand is coupled at the end of a polyethylene 
glycol (PEG) chain molecule which is already attached on the liposome’s surface 
(Zalipsky et al., 1997; Sudimack and Lee, 2000). 
In the current study, I have attached the peptide inhibitor (RI-OR2-TAT) onto 
the surface of nanoliposomes to improve its potency as a drug for inhibiting 
aggregation of amyloid-β in the brain. PINPs due to the presence of MAL-PEG 
molecules attached on their surface have the properties of stealth NPs and which can 
hide from the immune system – improving circulation time and bioavailability. Based 
on previous studies, RI-OR2-TAT has shown promising prospects such as BBB 
permeability and good stability in the blood circulation that would make it a suitable 
drug for the treatment of AD. A group of collaborating scientists in Italy have used an 
artificial cell BBB model with a monolayer of hCMEC/D3 cells in order to check the 
ability of PINPs to pass through the monolayer. The results of that experiment 
suggested that PINPs should across into the brain without any difficulty. In addition, 
PINPs themselves are not toxic to cells as they are composed of simple lipids and the 
peptide.  Previous to this project, the nanoliposomes were prepared in Italy, and 
specifically in Milano at the University of Milano-Bicocca, by Professor Massimo 
Masserini and Dr. Maria Gregori using cholesterol and sphingomyelin phospholipids 
(1:1/molar ratio) with 2.5% maleimide, and sent to us for analysis. One of the main 
aims of this project was to be able to manufacture and develop our own PINPs at 
Lancaster University, by producing the nanoliposomes, with their attached peptide, 
in a similar way to the Italian group, in three different sizes (50 nm, 100 nm and 200 
nm). Each PINP with approximately 100 nm diameter has ~1690 peptides molecules 
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attached, and could capture many Aβ monomers, oligomers or fibrils with the 









Figure 1.13: Possible mechanism of action of PINPs on Aβ monomers or oligomers. This illustration 
indicates the possible mechanisms by which PINPs could act on Aβ. Each red sphere represents a 
monomer of Aβ. The PEGylated liposome has the RI-OR2-TAT peptide attached on its surface and 
potentially captures monomers or oligomers, the latter involving multivalent interactions (A and C). 
Probably interactions with the charged region of the transit sequence as well as insertion of oligomers 






1.15 Scope of the Thesis 
The aims of the project are to investigate the best carrier technology for RI-peptide 
inhibitors.  
1. To produce and characterize (by size and shape-ultrastructure) simple, 
PEGylated liposomes and PINPs in three different sizes (50 nm, 100 nm and 
200 nm). 
2. To evaluate their ability to penetrate into neuroblastoma cells (SH-SY5Y).   
3. Finally to test whether the three types of liposomes were toxic to 
neuroblastoma cells (SH-SY5Y) and to examine their ability to inhibit the 
aggregation and toxicity of Aβ. 
Figure 1.14: The following illustration indicates the structure of the three types of liposomes. (A) 
Shows the illustration of a simple liposome (B) shows the illustration of a PEGylated liposome and (C) 





CHAPTER TWO – MATERIALS AND METHODS 
Table 2.1: Chemicals 
 
Table 2.2: Peptide inhibitor, Aβ42 
Peptide inhibitor (Ac-
rGffvlkGrrrrqrrkkrGyc-NH2) 
Cambridge peptides (Birmingham, UK) 





 Ammonium hydroxide 0.1 % 
 BBI solutions (gold nanoparticles) 
 Sepharose 4B-CL 
Agar Scientific (Cardiff, UK) 
DMEM-Dulbecco’s Modified Eagle 
Medium 
Lonza (Verviers, Belgium) 
 Chloroform 
 Sodium sulphate anhydrous 
AnalaR® (Poole, UK) 
Ethanol 70% Fisher Scientific (Loughborough, UK) 
PBS tablets Oxoid, IVD (Hampshire, UK) 
CellTiter 96® AQueous One Solution 
Reagent 
Promega (Madison, USA) 
 Bovine Serum Albumin (BSA) 
 Phosphotungstic acid 
 Ammonium Thiocynate 
 Iron (III) Chloride 
 Thioflavin -T 
 Fluoroshield™ with DAPI 
Sigma – Aldrich (Poole, UK) 
Kit Contents for BCA assay 
 Micro BCA Reagent A (MA) 
 Micro BCA Reagent B (MB)  
 Micro BCA Reagent C (MC)  
 
Thermo Scientific (Loughborough, UK) 
LabAssay™  Phospholipid Wako chemicals (Richmond, USA)  
Opti-MeM  Invitrogen - Gibco® (Carlsbad, CA, USA) 
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Table 2.3: Lipids 






SM No charge Avanti Polar 
Lipids Inc., U.S.A. 
Cholesterol (plant derived) 
 
CH No charge Avanti Polar 






PEG No charge Avanti Polar 





N/A No charge Avanti Polar 
Lipids Inc., U.S.A. 
Cholesterol 95% stabilized  CH No charge Acros Organics 
L-α-Phosphatidylcholine N/A No charge Sigma - Aldrich 
 
2.1 Buffers solutions 
 Phosphate Buffer Saline (PBS): 8g of NaCl (137 mM), 0.2g of KCl, 1.44g of 
Na2HPO4 and 0.24g of K2HPO4 were dissolved in 1L distilled deionized water 
to make a solution of 10 mM buffer pH 7.4.   
 PB: In addition, phosphate buffer was created by dissolving 8.4g of NaH2PO4 
with 15.62g of Na2HPO4 in 1L distilled deionized water to make a solution of 
10 mM buffer pH 7.4. 
 PB2S: Furthermore, PB2S was also created by dissolving 16g of NaCl (274 
mM), 0.2g of KCl, 1.44g of Na2HPO4 and 0.24g of K2HPO4 in 1L distilled 





2.2 Thioflavin-T (Th-T) preparation 
A stock solution was prepared by dissolving thioflavin-T in PB to make a 15 mM 
solution. This was stored in the dark at 4˚C for up to four weeks prior to use. 
 
 2.3 Amyloid-β splitting 
A volume of 2 mL of 0.1% NH4OH was added in hexafluoroisopropanol (HFIP) 
treated Aβ1-42 for 10 mins and then the sample was vortexed for 1 min. After that, 
the solution was divided into 10 Eppendorf tubes (0.2 mL in each tube). Then, the 
samples were then placed in a Speedvac (Savant, Thermo Scientific) with the lids 
open for 4 h until no sign of liquid remains in the tubes and a small pellet of Aβ 
remained (100μg Aβ). This stored at -30°C. 
 
2.4 Development of nanoparticles attached with RI-OR2-TAT by click chemistry 
(PINPs)  
2.4.1 Preparation and hydration of lipid film 
Two lipids (cholesterol and sphingomyelin) were dissolved in chloroform at 2.5 
mM of each one mixed with 5 molar % of MAL-PEG-PE. The lipid mixture with MAL-
PEG-PE was dissolved in chloroform. The liposome mixture was composed of a matrix 
of Sphingomyelin/Cholesterol (1:1 molar ratio) and containing 5% molar of MAL-PEG-
PE of total lipids (5 mM). Then, using the rotary evaporator (Rotavopor RII BÜCHI, 
Switzerland) the round bottom flask was attached to the distillation tube of the 
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evaporator and the flask was rotated for about 1 h at ~207 bar nitrogen pressure 
until the chloroform was evaporated from the flask and a thin lipid film was formed. 
After the evaporation of chloroform a thin lipid film was created, which was 
resuspended in filtered PBS, pH 7.3 at 5 mM lipid. Then, the hydrated lipid film was 
vortexed to detach the lipid film from the flask and the solution was stored overnight 
at 4°C.  
2.4.2 Freeze and thaw process 
Repeated freeze and thawing is the next experimental process required for the 
preparation of liposomes. This is necessary to produce liposomes smaller than 200 
nm and also creates unilamellar vesicles from multilamellar vesicles (Akbarzadeh et 
al., 2013; Traïkia et al., 2000; Sriwongsitanont and Ueno, 2011). The solution of 10 
mL of filtered PBS containing the lipid film was shaken well and vortexed until the 
thin lipid film was detached from the glass flask and was invisible by eye. Then, the 
liposome suspension was split by adding 1 mL into of each ten Eppendorf tubes. 
After that, each tube containing the lipid suspension was frozen for 15 secs in liquid 
nitrogen and immediately thawed using a heating block at 42°C. The freeze and thaw 
steps were repeated for 5 cycles for each tube. 
2.4.3 Bath sonication 






2.4.4 Vesicle extrusion 
The extrusion of unilamellar PEGylated liposomes was achieved by the use of 
AVANTI’s mini extruder. After the assembly of the mini extruder, the whole system 
was checked for any leaks by pumping filtered PBS through the two O-rings. The two 
Hamilton syringes were rinsed and filled with distilled water and then with filtered 
PBS. After checking the system from any leaks, the liposome suspension was added 
into one syringe with final volume 1 mL, and this was attached to the extruder and 
the vesicle solution was slowly passed through the membrane. This represents one 
passage. Eleven passages were performed for each sample. The same procedure was 
carried out to make liposomes of different sizes by using 50 nm, 100 nm and 200 nm 








Figure 2.1: AVANTI’s mini extruder. This picture shows all the parts (labelled) of the Avanti’s mini 




2.4.5 The attachment of peptide inhibitor on the surface of the liposome 
The covalent attachment of the peptide onto the surface of the liposomes 
using ‘click chemistry’ required an additional cysteine amino acid residue which was 
added at the N terminal end of the peptide inhibitor, resulting in Cys-RI-OR2-TAT (Ac-
rGffvlkGrrrrqrrkkrGyc-NH2). Once the extrusion of the PEGylated liposomes was 
completed, the peptide inhibitor was added at 2.5% of the total molarity of the 
liposome suspension (5 mM) and incubated for 2 h at 37°C (with vortexing once 
every hour) and then overnight at 4°C, to obtain the PINPs (in theory from the 5% of 
mal-PEG-PE the 2.5% was entrapped inside of the liposomes, while the rest 2.5% was 
attached on the surface of liposomes). In order to remove any unbound peptide 
inhibitor, the liposome suspension was purified by gel exclusion chromatography 
using a Sepharose 4B-CL column (18 cm x 1.6 cm) (see figure 2.2). The elution of 
PINPs after gel exclusion chromatography was assessed by DLS in order to determine 
the size of liposomes while the amount of bound peptide onto the surface of 
liposome was quantified using BCA assay and the amount of phospholipid present by 
LabAssay Phospholipid (WAKO). 
The above procedure describes the production of PINPs. In the case of MAL-
PEG liposomes, exactly the same procedure was followed with the only difference 
being that the attachment of the peptide inhibitor onto the MAL-PEG liposomes was 
not carried out. For the production of simple liposomes, no MAL-PEG-PE was added 
to the lipid suspension. In addition, the same procedure was carried out using 
different lipids and in some cases different molar ratios such as: (L-α-
Phosphatidylcholine/ cholesterol (1:1 molar ratio) and Sm/Chol/Fluor Cholesterol 
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(23-(dipyrrometheneboron difluoride)-24-norcholesterol-bodipy), (1:0.9:0.1 molar 
ratios). 
For the creation of fluorescent liposomes exactly the same procedure was used 
but instead of normal cholesterol some quantity of bodipy cholesterol was included 
at the above molar ratio. It is important to note that during the preparation of 
fluorescent liposomes the whole procedure was carried out in a dark room because 
fluorescent cholesterol is sensitive to light.   
Figure 2.2: Production of NL decorated with RI-OR2-TAT-Cys (purified) by click chemistry (PINPs). 
The illustration shows the production of liposomes from lipid film to PINPs. Free peptide inhibitor (RI-






2.5 Dynamic Light Scattering (DLS) analysis 
Nanoliposome size and polydispersity index (Pdl) were obtained by dynamic 
light scattering (DLS) at 25°C using a Zetasizer Nano ZS instrument, (Malvern 
Instruments Ltd., U.K.). For each liposome sample, 50 μL was added into a disposable 
solvent resistant micro cuvette. Particle size and polydispersity index were obtained 
from photon correlation spectroscopy, collecting backscattering at an angle of 173°. 
The data presented in the current thesis arise from the mean of three different 
measurements.  
 
2.6 Bicinchoninic acid (BCA) Assay 
Six diluted BSA standards were prepared from 0.02 mg/mL with the maximum 
BSA concentration at 200 μg/mL and the minimum at 0 μg/mL. After that, the 
Working Reagent (WR) was prepared by mixing in a clean glass bottle 25 parts of 
Micro BCA reagent A (MA), 24 parts of reagent B (MB) and 1 part of reagent C (MC) 
(25:24:1, Reagent MA:MB:MC) (Thermo SCIENTIFIC). Then, in a clear 96 well 
microplate (NUNCTM), 25 μL of the standard sample or the unknown sample plus 200 
μL of working reagent was added to each well.  The 96 well microplate was covered 
by sealing tape and incubated for 2 h at 37°C and then the absorbance of each well 
was measured at 562 nm on a plate reader (Wallac VICTOR2 1420 Multilabel Counter) 
using the  Pekin Elmer 2030 Manager program. Each sample was assayed in triplicate 
and the mean and standard deviation calculated. 
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2.7 Colourimetric determination of phospholipids with ammonium 
ferrothiocyanate (Stewart’s Method) 
Ammonium Ferrothiocyanate  
A 1L glass bottle was cleaned by distilled deionized water, and 0.4 mol 
ammonium thiocyanate NH4SCN (SIGMA – ALDRICH) and 0.06 mol iron (III) chloride 
(FeCl36H2O), (SIGMA – ALDRICH) were added. The solution was mixed well and 
stored at room temperature. 
Lecithin (L-a-phosphatidylcholine) preparation (Standard phospholipid solution) 
0.64 mM of L-a-phosphatidylcholine (SIGMA-ALDRICH) in 5 mL of chloroform 
(AnalaR®) was added to a round bottom flask. The solution was well shaken and 
vortexed for 2 mins and stored in the fridge at 4°C. 
Sphingomyelin standard solution Preparation (Standard phospholipid solution) 
0.5 g of sphingomyelin (Avanti Polar Lipids Inc., U.S.A) was dissolved in 5 mL of 
chloroform (AnalaR®) in a 5 mL round bottom flask. From this 5 mL sphingomyelin 
solution in chloroform at a concentration 0.1 mg/mL was prepared. The solution was 
mixed well and vortexed for 2 mins and stored in the fridge at 4°C. 
Generation of a calibration curve of sphingomyelin 
For the calibration curve to estimate liposome concentration, six dilutions of 
sphingomyelin were prepared. The six concentrations were: 0.1 mg/mL, 0.08 mg/mL, 
0.06 mg/mL, 0.04 mg/mL, 0.02 mg/mL and 0 mg/mL. Each dilution had final volume 1 
mL. For the preparation of the six standards sphingomyelin solution and chloroform 
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was used. Into each dilution, 1 mL of ammonium ferrothiocyanate was added, and 
the mixture was mixed well and then centrifuged (MIKRO 120Zentrifugen 
2RPMx1000 for 5 mins. After centrifugation, two layers were formed. The lower layer 
(chloroform) was removed with a glass Pasteur pipet. The chloroform phase then 
was added in a glass cuvette (Hellma Quartz Cuvette) and the optical density read at 
λ 490 nm.  
Colourimetric determination of phospholipids in liposomes 
The same procedure as above was carried out using the liposomes mixtures, 
and the absorbance compared to a standard curve was obtained to determine the 
concentration of phospholipid in each suspension. These liposomes mixtures were 
plain liposomes, MAL-PEG liposomes or PINPs.  
 
2.8 Phospholipid Assay – Choline oxidase · DAOS method (Wako assay) 
This assay was used as an alternative of Stewart’s assay because we had some 
technical issues and did not work properly. The quantification of sphingomyelin in 
liposomes was performed by using an enzyme assay, Wako LabAssay Phospholipid B 
test kit. This assay is based on phospholipids such as lecithin, lysolecithin and 
sphingomyelin. In this case the assay is based on sphingomyelin in a sample which 
hydrolyzed to choline by phospholipase D enzyme. This phospholipid assay is based 
on an enzymatic reaction using N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-




Preparation of reagents: 
 Colour Reagent: 50 mL of chromogen substrate were dissolved into 50 mL of 
buffer (1:1). The mixture was mixed well and stored at 4˚C.   
Preparation of standard solution (microplate method): 
 This phospholipid assay used three standards with following concentrations 
(see table 2.4). In the current experiment the standards were diluted in 1:20 by 
giving the follow concentrations: (a) 7 mg/dL, (b) 15 mg/dL and (c) 29.8 mg/dL. 
Table 2.4: This table shows how to prepare the three phospholipid standards for the Wako assay 
 
Perform the assay in a clear 96 well plate: 
The three standards were added in a final volume of 300 μL into each well. As 
regards for the liposome sample solutions, 25 μL of each liposome suspension were 
added to each well plus 275 μL of colour reagent to the same wells in order to make 
a final volume of 300  μL. The plate was shaken well and incubated at 37˚C for 5 
mins. After the incubation of the plate, the absorbance at 600 nm using the plate 









1 100 μL 100 μL 2 μL 150  mg/dL 
2 Undiluted - 2 μL 300  mg/dL 
3 Undiluted - 4 μL 596.1  mg/dL 
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2.9 Concentrate the liposomes 
After the determination of PINPs using the BCA and phospholipid assay, the 
fractions were collected in two centrifugal concentrator tubes (Vivaspin 6) in equal 
volumes and spun at 4000 rpm (3000xg), at 4°C for approximately 15 mins. After 
spinning, the liposomes were collected. 
 
2.10 Preparation of three types of liposomes for Transmission Electron Microscopy 
(TEM) 
2.10.1 Staining of plain, MAL-PEG-PE liposomes and PINPs for TEM 
For the staining of liposome samples, the heavy metal 2 % phosphotungstic 
acid (PTA) (SIGMA-ALDRICH) was used. For its preparation 6.94 x μmol of PTA was 
dissolved in 1 mL of distilled water. Then, the solution was vortexed for 1 min and 
centrifuged (MIKRO 120Zentrifugen 14000 rpm) for 5 mins. 
The liposome suspension was pipetted onto copper grids (G2004, 400Thin, copper 
3.05 mm - ATHENE). On the shiny side of the grid one drop (1 mM) of liposome 
suspension was added for 2 mins until the liposomes particles were adsorbed and 
the surplus was removed carefully with clean filter paper. After that, a drop of 2% 
(w/v) of PTA (5 μL) was added and left for 2 mins. The surplus PTA was also removed 
with filter paper and the sample was dried at room temperature. Finally, the grids 
were stored in a glass petri dish with the shiny side facing upwards until the sample 
was ready for examination under TEM (JEOL JEM 1010). EM pictures were taken by 
Dr. Nigel Fullwood.  
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2.10.2 TEM photographic image processing  
After the examination of samples under the TEM, the film plates which were 
located in the TEM were collected for further processing. The dehydration of film 
plates using vacuum dessicator was a necessary step before the development of 
pictures. Next, the exposed film plates (Kodak Electron Microscopy Film 4489, Agar 
scientific, UK) were placed in a black developing rack. The rack was immersed in a 
black container which contained developer (Ilford phenisol developer) for 4 mins (1 
part developer to 4 parts distilled water). The temperature of the developer was 
approximately 20°C. Next, the developing rack was transferred into another 
container which contained water and immersed for 1 min. Afterwards, the rack was 
placed into the fixation solution (Ilford hypam fixer) for 5 mins. At each stage, the 
developing rack was agitated in order to promote the even development of films. 
Then, the rack was placed into a running bath water for 2 h with 5 drops of wetting 
agent (Kodak foto – flo). The whole process was carried out in a dark room. After 
that, the racks were store in a drying cabinet to air-dry (Baird and Tatlock Ltd, UK) 
overnight. Finally, the developed images were scanned using an EPSON Scanner and 








2.11 Toxicity assays 
2.11.1 MTS cell proliferation colorimetric assay Kit 
For this assay, SHSY-5Y human neuroblastoma cells were used. The culture and 
the splitting of cells were done by maintaining the cells in Dulbecco’s Modified Eagle 
Medium (DMEM, Gibco) containing 10% Fetal Calf Serum, 100 U/mL penicillin, 50 
µg/mL streptomycin, at 37°C and 5% CO2 in a humidified incubator. The cultured 
SHSY-5Y human neuroblastoma cells were transferred into a sterile 96 clear well 
growth plate (100 μL at ~20,000 cells) per well and were incubated for 24 h at 37°C 
in order to adhere into the base of each well. After 24 h incubation of cells, the 
media was removed and the different dilutions of the three types and sizes of 
liposomes were added, in order to check the toxicity of liposomes. In order to test 
the toxicity of the three sizes (200, 100 and 50 nm) and the three types of liposomes 
(simple, PEGylated and PINPs), dilutions of liposomes with DMEM were prepared at 
four different concentrations: 50 μm, 10 μm, 1 μm and 0.1 μm. In addition, 100 μL of 
each size and each concentration of liposomes was added in each well in growth 
medium (four wells per condition) and the plate was incubated again for 24 h. Then, 
the viability of SHSY-5Y cells or the toxicity of liposomes was assessed using the 
CellTiter 96AqueousOne Solution Cell Proliferation (MTS) Assay (Promega) kit. The 
sterile 96-well plate (COSTAR®) was incubated for 2 – 4 h at 37°C in a humidified, 5% 
CO2 atmosphere and then the plate was read at 490 nm on a plate reader (Wallac 
VICTOR2 1420 Multilabel Counter). Furthermore, for the experiments which 
examined the ability of PINPs and MAL-PEG liposomes to affect the amyloid beta 
aggregation and protect against Aβ cytotoxicity the cell growth medium from DMEM 
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was changed to Opti-MeM (Invitrogen) while the Aβ1-42 had been pre-aggregated (for 
24 h at 25°C in filtered PBS) was added to a concentration of 5 µM. The plates were 
incubated again for 24 h and the viability of cells was examined as above. 
As referred above, the MTS assay examines the viability of cells. The compound 
which added into the cells (MTS tetrazolium) reacts with the cells and has the 
property to self-reduce into another compound called formazan. This coloured 
formazan product is soluble in culture medium. The chemical reaction occurs due to 
the production of NADPH or NADH by dehydrogenase enzymes in metabolically 
active cells (WWW, Promega). 
 
2.11.2 Thioflavin-T (ThT) assay  
Th-T assay was performed using HFIP-treated synthetic Aβ1-42 peptides. Th-T 
binds to fibrils as they form. Th-T is used for the identification and quantification of 
Aβ fibrils. When Th-T is added in a sample which contains β-sheet-rich structures 
such as Aβ, it reacts because Th-T creates micelles which bind to amyloid fibrils and 
produce a strong fluorescent signal (Hudson et al., 2009). The Aβ was dissolved in PB 
to give a final concentration of 100 μM. Two types of liposomes (PEGylated 
liposomes and PINPs) were tested in this assay in order to examine if they are 
capable of inhibiting the aggregation of Aβ. Th-T assay was conducted in 384 well 
black (Corning) microtitre plate with clear bottom, with 25 µM Aβ-42, 15 µM Th-T, 
and a range of concentrations of PINPs and PEGylated liposomes, in 10 mM PBS, pH 
7.4, with a total reaction volume of 60 µL and Th-T fluorescence was monitored 
every 10 mins. Apart from the first wells which contained Aβ+Th-T+PBS in order to 
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define the maximum aggregation of Aβ, the rest of the wells of the plate contained 






Figure 2.2: This illustration shows the amount and the sequence which each reactant into the wells for 
the Th-T assay. 
 
After the filling of the plate with the corresponding samples and concentrations 
of liposomes the 384 well (Corning) microtitre plate was sealed with a transparent 
film to prevent any evaporation of the samples and the accumulation of fibrillar Aβ 
was monitored using a BioTek Synergy plate reader (λex = 442 nm, λem = 483 nm) 
over 48 h at 25˚C. Each condition was assayed three times and the final result for 







2.12 Cell penetration assay  
In order to test whether the liposomes were able to penetrate into the 
neuroblastoma cells (SHSY-5Y), they were incubated together with the cells in 
complete medium (DMEM) as standard mammalian cell culture conditions for 24 h. It 
is important to note that, in this assay, fluorescent (bodipy) cholesterol had replaced 
some of the normal cholesterol in the liposomes (see above). In this assay the 
neuroblastoma cells were grown in a 6 well plate using DMEM as growth medium. 
Cover slips were presented in each well allowing the growth of cells on the surface of 
the coverslips. The cells were incubated for 24 h at 37°C in order to adhere on the 
surface of coverslips. Then, different concentrations of 200 nm of PEGylated 
liposomes and PINPs (0.1 μM, 1 μM and 10 μM) were added in each well and the 
plate was incubated for 1 h at 37°C. After that, using a needle, the cover slips from 
the wells of the plate were transferred onto the slides and specifically the side of 
cover slip with the cultured cells was put upside down in order for the side with cells 
to touch the drop of Fluoroshield™ with DAPI (4’, 6-diamino-2-phenylindole 
dihydrochloride) (Sigma – Aldrich) which was already added onto the slide. Then, the 
samples were examined under a confocal microscope (LSM 510 – Laser Module – 





CHAPTER THREE - DLS RESULTS 
3.1 Conjugation of RI-OR2-TAT-Cys peptide to PEGylated liposomes to create PINPs 
According to a previous study (Parthsarathy et al., 2013), a TAT sequence was 
added onto the RI-OR2 peptide creating a more efficient peptide to inhibit Aβ 
aggregation, but which also allowed it to penetrate into cells and cross the BBB 
successfully. Further studies showed that the peptide could be made more potent by 
combining it with nanomedicine. In the current study, I have covalently attached the 
RI-OR2-TAT peptide to liposomes by ‘click chemistry’. A cysteine residue added to C-
terminus of the RI-OR2-TAT peptide provides a thiol group which reacts with a 
maleimide-functionalized phospholipid (mal-PEG-PE) present on the surface of the 
nanoliposomes, creating a complex between the peptide inhibitor and the liposomes 
(see figure 3.1).   
Figure 3.1: This illustration shows the creation of PINP through ‘click chemistry’ using the peptide 






3.2 Characterization of liposomes by size 
After the preparation of liposomes, the diameter, the polydispersity and the 
stability of each distinct size (50 nm, 100 nm and 200 nm) and type (plain, mal-PEG-
PE, PINPs) of nanoliposomes were assessed using Dynamic Light Scattering (DLS) 
(Zetasizer Nano ZS, Malvern Instruments Ltd., U.K.). The different sizes of the three 
types of liposomes were examined (by DLS) in several conditions such as:  
 Liposome suspensions at different dilutions (different concentrations).  
 By heating the extruder to 75°C.  
 Preparation of liposomes by applying the freeze and thaw process using liquid 
nitrogen and bath sonication.  
 Preparation of liposomes without these methods.  
Before testing any of the nanoliposomes, standard gold nanoparticles of four distinct 
sizes (2 nm, 10 nm, 20 nm and 100 nm) were examined in order to calibrate the 
system and determine how consistent DLS is for measurement of these standard 
nanoparticles.  
 
3.2.1 Characterization of standard gold nanoparticles using DLS 
The consistency of DLS was examined using four different distinct sizes (2 nm, 
10 nm, 20 nm and 100 nm) of gold colloids (BBI, Agar Scientific) in order to cover a 
wide spectrum of sizes. Each size of gold nanoparticle was examined at three 
different dilutions (1:500, 1:250, and 1:125) in order to determine and compare 





















affect the measurements using DLS. The different dilutions were prepared using 
filtered Phosphate Buffered Saline (PBS). Before the preparation of MAL-PEG 
liposomes and PINPs, we experimented on simple liposomes using them in different 
experiments as shown below.   
100 nm gold nanoparticles: 
Starting with the largest nanoparticles of 100 nm, the gold nanoparticles 
dilution of 1:500 gave a mean size ± standard deviation (±SD) of 94.46 ± 3.4 nm, the 
dilution of 1:250 gave a mean size of 96.91 ± 3 nm and the dilution of 1:125 gave a 
mean size of 94.60 ± 3.1 nm (see figure 3.2). 
Figure 3.2: The graph shows the average diameter of 100 nm gold nanoparticles at different 
dilutions. Bars show the mean ± SD of 100 nm gold nanoparticles after three measurements (n=3). The 
























20 nm gold nanoparticles: 
For the 20 nm standard gold nanoparticles the dilution of 1:500 gave a mean size of 
38.14 ± 5.72 nm while the dilution of 1:250 gave a mean size of 44.47 ± 12.6 nm and, 
finally, the dilution of 1:125 gave a mean size of 27.6 ± 18.14 nm (see figure 3.3). 
Figure 3.3: The graph shows the average diameter of 20 nm gold nanoparticles at different dilutions. 
Bars show the average diameters for each dilution after three measurements. The x-axis describes the 
different dilutions, while the y-axis describes the diameter recorded by DLS. All values were slightly 
higher than expected, with relatively large ± SD. 
 
10 nm gold nanoparticles: 
For the 10 nm gold nanoparticles the dilutions of 1:500, 1:250 and 1:125 gave mean 























Figure 3.4: The graph shows the average diameter of 10 nm gold nanoparticles at different dilutions. 
Bars show the average diameters ±SD for each dilution, after three measurements. The x-axis 
describes the different dilutions, while the y-axis describes the diameter recorded by DLS. The values 
were higher than expected.  
 
2 nm gold nanoparticles:  
The measurements of 2 nm standard gold nanoparticles were of little relevance 
to the work with liposomes, but it was a challenge to determine the ability of DLS to 
measure nanoparticles with a very small diameter. For the dilutions of 1:500, 1:250, 
1:125 and 1:50, DLS gave mean sizes of 0.72 ± 0.0085 nm, 1.79 ±0.66, 1.1 ± 0.34 nm 
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Figure 3.5: The graph shows the average diameter of 2 nm gold nanoparticles at different dilutions. 
Bars show the average diameters ± SD for each dilution after three measurements. The x-axis describes 
the different dilutions, while the y-axis describes the diameter recorded by DLS. The different dilutions 
gave a variety of values but with dilutions of 1:50 and 1:250 the results were quite accurate and close 
to 2 nm. 
 
Size distribution of 100 nm gold nanoparticles  
In order to examine how DLS tests perform with nanoparticles of different 
concentrations, the size distribution of  100 nm gold standard nanoparticles was 
determined at two different concentrations (at high and low concentration). As can 
be seen from figure 3.6, which shows the measurement of 100 nm particles at high 
concentration, multiple peaks were present indicating that DLS detected more than 
one population, with a high polydispersity index. On the other hand, the examination 
of a more diluted sample (low concentration) gave more accurate and more reliable 
results with a single peak which indicates one population with low polydispersity, as 






























Particle diameter (nm) 
Figure 3.6: The graph represents the size distribution of 100 nm liposomes at 2.5 mM concentration. 
The graph shows a concentrated sample of 100 nm liposomes which reveals multiple peaks with high 
polydispersity index. The red dashed line indicates the spectrum of size of the nanoparticle population 
while the black arrows indicate the highest percentage of nanoparticle population in the specific 
spectrum.  
Figure 3.7: The graph shows the size distribution of 100 nm liposomes at 10 μM concentration. The 
graph shows a sample of 100 nm liposomes at an appropriate (low) dilution which reveals a single 



























Dilutions of different sizes of gold nanoparticles
Consequently, based on these different concentrations of standard gold 
nanoparticles, I concluded that the correct dilution is needed to give the most 
reliable and most accurate results. For the 100 nm gold particles the dilution 1:250 
gave a mean value of 96.91 nm, for the 20 nm particles the most reliable dilution was 
1:500 which gave a mean value of 27.6 nm, for the 10 nm particles the dilution 1:250 
gave a mean value of 28.01 nm and, finally, for the 2 nm particles the most accurate 
dilution was 1:50 which gave a mean value of 2.1 nm (see figure 3.8). Once the 
measurements of standard gold nanoparticles were completed and the consistency 
of DLS was assessed, the three sizes of NL prepared at Lancaster were examined, 
starting from simple liposomes.  
Figure 3.8: The graph shows the average diameter of gold nanoparticles using DLS at the most 
accurate dilutions. Bars show the most accurate average (± SD) at different dilutions for 100 nm, 20 
nm, 10 nm and 2 nm gold nanoparticles (n=3). The x-axis describes the sizes of the gold nanoparticles, 



































3.2.2 Characterization of simple liposomes using (DLS) 
Simple liposomes were composed of sphingomyelin and cholesterol (1:1 molar 
ratio), the first stage of making PINPs. The size of simple liposomes was examined by 
DLS using liposome suspensions at different dilutions (based on the standard gold 
nanoparticle results) in filtered PBS for the three different sizes (200 nm, 100 nm and 
50 nm). 
 
200 nm Simple liposomes 
For the 200 nm simple liposomes the dilutions 1:500, 1:250, 1:50, 1:20, and 
1:10 gave mean sizes of 173.9 ± 4.95 nm, 153.1 ± 5 nm,  216 ± 5 nm, 200.4 ± 5.6 nm  
and 167.9 ± 4.3 nm respectively (see figure 3.9). 
Figure 3.9: The graph shows the average diameter of 200 nm simple liposomes at different dilutions. 
The x-axis describes the different dilutions, while the y-axis describes the mean diameter ± SD (n=3) 
recorded by DLS. A variety of values was observed at the different liposomes dilutions with the most 










































100 nm Simple liposomes 
The size of 100 nm simple liposomes was also examined at different dilutions of 
1:500, 1:250, 1:125, 1:50, 1:20, and 1:10  which gave mean sizes of 109.23 ± 9.2 nm, 
119.1 ± 26.2 nm, 109.2 ± 7.75 nm 149.2 ± 7.4 nm, 120 ± 3 nm and 125.3 ± 7.2 nm, 
respectively (see figure 3.10).  
Figure 3.10: The graph shows the average diameter of 100 nm simple liposomes at different 
dilutions. A variety of values was observed at the different liposome dilutions with the closest to 
expected values (109.2 and 109.23 nm) observed at dilutions of 1:500 and 1:125. 
 
50 nm Simple liposomes 
The measurements for 50 nm nanoliposomes at different dilutions of  1:500, 
1:250, 1:125, 1:50, 1:20, and 1:10 gave mean sizes of 95.5 ± 5 nm, 87 ± 2.9 nm, 82 ± 













































Figure 3.11: The graph shows the average diameter of 50 nm simple liposomes at different dilutions. 
A variety of values was observed at the different liposomes dilutions with the most accurate value 
(84.59 and 84.65 nm) at dilutions of 1:250 and 1:125. However, all values were slightly larger than 
anticipated.                                                                                                                                    
 
The measurements for the 50 nm simple liposomes were higher than expected, 
as can be observed from figure 3.11. These measurements were lower than those 
obtained for 100 nm liposomes, but were closer to 100 nm than 50 nm. So in order 
to attempt to get more reliable values (closer to 50 nm) the liposome mixture was 
extruded initially through a 200 nm polycarbonate membrane for 5 passages, then 5 
passages through a 100 nm  polycarbonate membrane, and, finally, the liposome 
suspension was extruded through a 50 nm polycarbonate membrane for 11 
passages. Despite all these extrusions through the three different polycarbonate 
membranes, the mean size of the 50 nm simple liposomes did not change greatly, 







































1:10, giving mean sizes of 78.34 ± 4.3 nm, 86.13 ± 5.72 nm and 85.08 ± 7.2 nm, 
respectively (see figure 3.12). 
Figure 3.12: The graph shows the average sizes of 50 nm simple liposomes at different dilutions after 
extrusion through 200 nm, 100 nm and, finally, 50 nm polycarbonate membranes. 
Observations using simple liposomes 
Taking into consideration the above results, it was observed that the 100 nm 
simple liposomes gave the most reliable results, having an average mean size in the 
different dilutions very close to 100 nm, with relatively low standard deviation 
compared to the 50 nm and 200 nm nanoliposomes. Consequently, as the 100 nm 
liposomes had the more reliable results, they were used for further experiments to 
examine their size and their polydispersity at 4, 8 and 11 passages, and also by 
heating the extruder block at 75°C compared to room temperature. In addition, the 
liposome size was examined in liposomes suspensions which had undergone 
sonication and a freeze and thaw process and for liposomes solutions which did not 




































Number of passages 
100 nm liposomes at 4, 8, 11 and 14 passages through the extruder at room 
temperature 
As can be seen from figure 3.13, the mean size of the 100 nm liposomes 
gradually decreased as the number of passages through the membranes was 
increased. Initially the size of liposomes at 4 passages was 189 ± 40.9 nm, at 8 
passages this decreased to 135.2 ± 13.2 nm, while at 11 passages the size decreased 
again to 114.5 ± 4.3 nm and finally at 14 passages the size of liposomes (113.1 ± 3.61 
nm) did not change significantly from that obtained at 11 passages.  
Figure 3.13: The graph shows and compares the average size of 100 nm simple liposomes at 4, 8, 11 
and 14 passages through the Avanti’s mini extruder at room temperature. The x-axis describes the 
number of passages through the 100 nm membrane and the y-axis describes the diameter recorded by 






Dispersity of 100 nm liposomes and number of passages through the extruder at 
room temperature 
This experiment illustrates the importance of the number of extrusions of the 
liposome suspension, in order to give the most accurate and suitable size of 
liposomes, with a less polydisperse nanoliposome population. Polydispersity index 
(pdl) is a parameter of DLS which measures the heterogeneity of sizes of particles in a 
mixture (see figure 3.14). According to figures 3.15 and 3.16, it is clear that as the 
number of passages increases, the percentage of pdl decreases, giving a population 
which is more monodisperse and less polydisperse.  
Figure 3.14: Dispersity of nanoliposomes. This illustration shows the two cases of dispersity of 
liposomes in a suspension. The illustration on the left shows a liposome suspension with a uniform 
population of liposomes (same size, mass and shape - i.e. low pdl) while the illustration on the right 
shows a liposome suspension with a non-uniform population of liposomes (inconsistent size, mass and 


























Figure 3.15: The graph describes the polydispersity of different populations of 100 nm simple 
liposomes produced by increasing number of passages through the extruder at room temperature. 
The calibration curve shows a near linear correlation, where the x-axis expresses the number of 
passages through the extruder, and the y-axis describes the recorded liposome pdl by DLS. As the 
number of passages increases the polydispersity decreases. 
Figure 3.16: The graphs show the change of size distribution of 100 nm simple liposomes with 
increased number of passages. As the number of passages increases the population distribution of 
100 nm simple liposomes becomes closer to 100 nm (A = zero passages, B = 4 passages, C = 8 passages 






































Number of Passages 
On the other hand, in the case of liposome extrusion at 75°C the mean size of 
nanoliposomes (NL) was maintained at almost the same level for all passages. The 4th 
passage gave a mean size of 112.23 ± 3.38 nm, compared to 113.66 ± 6.5 nm at 8 
passages, 112.86 ± 2.45 nm at 11 passages and 112 ± 6.4 nm at 14 passages (see 
figure 3.17). This illustrates the fact that liposome membranes become more fluid at 
high temperatures and so can pass more easily through the polycarbonate 
membrane filter, and in this case an accurate size is obtained from only the first four 
passages (Los and Murata, 2004). 
Figure 3.17: The graph shows and compares the average size of 100 nm simple liposomes at 4, 8, 11 
and 14 passages through the Avanti mini extruder at 75°C. The increase of temperature makes the 
liposomes more fluid and so they can pass through the polycarbonate membrane more easily. 


























Figure 3.18: The graph describes the polydispersity of different populations of liposomes in a 100- 
nm simple liposome solution after four different passages through the extruder at 75°C. The 
calibration curve suggests a non-linear correlation, where the x-axis expresses the number of passages 
through the extruder, and the y-axis describes the polydispersity by DLS. 
 
Furthermore, the polydispersity parameter of the liposomes was also tested for 
the other sizes that were investigated. With regard to the polydispersity of the three 
sizes of liposomes, it was found that for nanoparticles of 50 nm and 200 nm, the 
percentage of polydispersity after 11 passages through the appropriate 
polycarbonate membrane was higher than that obtained for the 100 nm liposomes. 
Accordingly, the populations of 50 nm and 200 nm liposomes were more 











































Table 3.1: The table shows the size and the polydispersity of different populations of 50 nm, 100 nm 
and 200 nm simple liposome suspensions after 11 passages through the extruder at room 
temperature (n=3). All values presented low percentage of polydispersity but 50 and 200 nm 
liposomes were more polydisperse than 100 nm liposomes.  
In addition, the size of NL was examined by comparing two samples of 100 nm 
liposomes (one of which had undergone sonication and freeze/thaw process and the 
other which did not), it is clearly that the liposome suspension which had undergone 
freeze/thawing, had a smaller diameter closer to 100 nm compared to the untreated 
liposome suspension. The two samples were measured by DLS at different dilutions 
(see figure 3.19). 
Figure 3.19: The graph shows the average size of two liposome suspensions at different dilutions 
prepared with and without sonication followed by freeze/thawing. The blue bars represent the 
liposome suspension which had undergone sonication and a freeze/thaw process and the red bars 
represent the liposome suspension which did not undergo either of these two procedures. The black 
dashed line represents 100 nm and it can be seen that the blue bars are closer to this value.  
Simple liposomes at room temperature 




50 nm 75.34 nm ± 4.35 0.233 
100 nm 104.2 nm ± 3.01 0.092 
200 nm 214.4 nm ± 5.66 0.139 
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After the evaluation of the size and the polydispersity of the three distinct sizes 
of simple liposomes, their stability (the ability of the liposomes to maintain a 
constant spherical shape and diameter) was also examined during storage for 6 
months at 4°C. During first two months, the liposome suspensions were measuring at 
more frequent periods. The mean size for the 200 nm simple liposomes ranged from 
229 nm (highest) to 159 nm (lowest), and as can be seen from figure 3.20, the mean 
size of liposomes during the 1st month remained close to 200 nm, but this fell to 
~160 nm during months 2, 3 and 4. In contrast, the 100 nm and 50 nm liposomes 
appear to have a more stable size on long term storage, with the 100 nm liposomes 
in particular maintaining an almost constant size very close to 100 nm. The 
measurements for the 50 nm liposomes were relatively stable but were higher than 
the expected values. The mean values of 50 nm simple liposomes over six months 

























Figure 3.20: The graph shows the stability of the three different sizes of simple liposomes over 180 
days at 4°C. The 100 nm liposomes seem to be the most stable compared to the other sizes (50 and 
200 nm) and maintain their size stability for up to 6 months. 
 
3.2.3 Characterization of MAL-PEG liposomes by size using DLS 
PEGylated liposomes are simple liposomes which have 1,2-distearoyl-sn-
glycero-3 phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] (mal-PEG-
PE) incorporated into them. The inclusion of mal-PEG-PE into the liposomes offers 
the ability to improve their circulation times, maximize delivery, and produce PEG-
lipid conjugates for the incorporation of targeting agents (Wang, et al., 2012). In the 
following section of the thesis, three distinct sizes (200, 100 and 50 nm) of PEGylated 






























200 nm PEGylated liposomes 
In contrast to the 200 nm diameter simple liposomes, the 200 nm PEGylated 
liposomes at different dilutions gave more stable mean diameter sizes, with values 
closer to 200 nm. Dilutions of 1:500, 1:250, 1:125, 1:50 and 1:10 gave mean (±SD) 
sizes of 222.47 ± 19.28 nm, 245.3 ± 11.86, 201 ± 12.7 nm, 221 ± 20.6 nm and 195.7 ± 





Figure 3.21: The graph shows the average sizes of 200 nm MAL-PEG liposomes at different dilutions.  
Bars show mean ± SD (n=3) for the different, dilutions. All of them are close to the expected value, but 
the most accurate sizes (201.1 nm and 195.73 nm) were obtained at dilutions of 1:125 and 1:10, 
respectively.  
 
100 nm PEGylated liposomes 
For the 100 nm PEGylated liposomes, the dilutions 1:500, 1:250, 1:50, 1:20 gave 
mean diameters of 102 ± 1.58 nm, 110.9 ± 2.91 nm, 106.5 ± 1.53 nm and 113.5 ± 

























































Figure 3.22: The graph shows the average sizes of 100 nm MAL-PEG liposomes at different dilutions. 
Bars show mean ± SD (n=3) for the different dilutions. The values are similar at the different, dilutions, 
with the most accurate sizes (102. 2 nm and 106.53 nm) obtained at dilutions of 1:500 and 1:125, 
respectively. 
50 nm PEGylated liposomes 
In the case of the 50 nm PEGylated liposomes the different dilutions of 1:500, 
1:250, 1:50, 1:20 gave mean diameters of 58 ± 7.33 nm, 77.16 ± 4.43 nm, 82.33 ± 4.9 


















Sizes and dilutions of the three types of MAL-PEG liposomes
Figure 3.23: The graph shows the average sizes of 50 nm MAL-PEG liposomes at different dilutions 
(n=3).  Bars show ± SD (n=3) for the different dilutions. The closest to the predicted value (58.05 nm) 
observed at a dilution of 1:500.  
In general, the three different sizes of PEGylated liposomes gave variety of 
diameters at the different dilutions, which is an indication that the concentration of 
liposomes in a solution can affect the measurements by DLS. The closest value to the 
predicted size measurement of each PEGylated liposome preparation at its optimal 
concentration is plotted in figure 3.24, and the polydispersity of the different sizes at 
specific dilutions was also estimated (table 3.2). 
Figure 3.24: The graph shows the average diameters of 200, 100, and 50 nm MAL-PEG liposomes at 
different dilutions. Bars (mean ± SD, n=3) show the dilutions required to give the most accurate size 
measurements of PEGylated liposomes of three distinct sizes. 
PEGylated liposomes at room temperature 




50 nm 58.7 nm ± 7.33 0.202 
100 nm 102 nm ± 1.58 0.128 
200 nm 201 nm ± 12.7 0.241 
Table 3.2: This table shows the size and the polydispersity of different populations of 50 nm, 100- 
nm and 200 nm PEGylated liposomes after 11 passages through the mini extruder at room 
temperature. The 100 nm PEGylated liposomes presented the lowest polydispersity compared to 50- 




























As for the simple liposomes, the PEGylated liposomes were also characterized 
by DLS for their stability at 4°C for up to 120 days. The size and the polydispersity 
index indicated that sizes of liposomes with mal-PEG molecule incorporated into 
them remained stable for the 50 nm and 100 nm PEGylated liposomes, but 
decreased over time for the 200 nm PEGylated liposomes (figure 3.25). As can be 
seen from this figure, most stable liposome size was, again, 100 nm.  
Figure 3.25: The graph shows the stability of the three different sizes of PEGylated liposomes over 
120 days at 4°C. The 100 nm liposomes proved to be more stable and closer to their expected size than 
those of 100 and 200 nm diameter. The 200 nm PEGylated liposomes present a gradually decrease in 






3.2.4 Characterization of Peptide Inhibitor Nanoparticles (PINPs) using DLS 
After the extrusion of PEGylated liposomes through the appropriate 
polycarbonate membranes, the RI-OR2-TAT-Cys peptide inhibitor was attached on 
the surface of the liposomes by reaction with the maliemide - PEG molecule. As the 
two intermediates stages of PINPs (simple and PEGylated liposomes) were measured 
by DLS, thus purified PINPs were also examined by DLS at different dilutions (see 
figures 3.29 - 3.31). Measurements of MAL-PEG liposomes and PINPs were taken in 
order to examine how the presence of inhibitor peptide on the MAL-PEG molecule 
affects the DLS measurements. The measurements of both types of more complex 
liposomes were compared with simple liposomes. 
Micro BCA protein assay 
After the purification of PINPs by gel exclusion chromatography using a 
sepharose 4B-CL column, the fractions were examined by a Micro BCA protein assay 
in order to quantify the amount of peptide bound to liposomes and identify the 
fractions containing the PINPs. The standard curve for this assay was plotted by the 
measurement of six different dilutions of Albumin (BSA), with a read out of 
absorbance at 562 nm (see figure 3.26). The protein content of the PINPs was 
measured in the same way.  The initial column fractions did not contain any protein, 
but as the sample of liposomes (in filtered PBS) ran through the column, the PINPs 
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Figure 3.26: Standard curve for BSA in the micro plate BCA protein assay. This curve indicates a linear 
correlation between protein content and absorbance (n= 1).  
Figure 3.27: Elution profile following the purification of PINPs on a Sepharose 4B-CL column. The x-
axis indicates the fraction number while the y-axis gives a measure of protein concentration in BCA 
assay, as indicated by absorbance at 562 nm. The red numbers shows the fractions with the highest 





LabAssay Phospholipid (WAKO)   
After extrusion and column chromatography of the liposome suspension, 
phospholipid recovery was initially determined by phosphorous assay using the 
method of Stewart (Stewart, 1980). However, this method was not successful, and so 
another different phospholipid assay was used. This was the LabAssay (WAKO) 
phospholipid assay, which should determine the phospholipid content 
(sphingomyelin) of the liposomes, which were composed of two main lipids, 
cholesterol and sphingomyelin (1:1 molar ratio). This WAKO assay was more 
successful at determining the concentration of the lipid content of the liposomes and 
comparing it with the expected initial concentration (5 mM). 
For example if PINPs were collected in two equal fractions, theoretically that 
means that each one of these two fractions has 2.5 mM of liposome suspension (2.5 
mM + 2.5 mM = 5 mM). In other words, each fraction of PINPs contains 1.25 mM 
sphingomyelin and 1.25 mM cholesterol (molar ratio 1:1). The WAKO assay was able 
to quantify only the sphingomyelin based on an enzymatic reaction. Consequently, 
the values from the WAKO assay for each fraction, as determined from the standard 


















































Figure 3.28: The graph shows the absorbance (600 nm) of the three phospholipid standards (n= 1) as a 
function of phospholipid concentration (mg/dL) in the WAKO LabAssay. 
200 nm PINPs 
The 200 nm PINPs at different dilutions of 1:125, 1:50, 1:20 and 1:10 gave a 
mean size of 228.27 ± 19.77 nm, 174 ± 14.57 nm, 161.8 ± 14.43 nm and 155.23 ± 




Figure 3.29: The graph shows the average sizes of 200 nm PINPs at different dilutions, as 
determined by DLS. Bars (mean ± SD, n=3) show a variety of values at the different liposome dilutions, 






























100 nm PINPs 
The 100nm PINPs were examined at different dilutions using DLS, but, as can 
be observed from the figure 3.30, their size estimates gave higher values than those 
obtained for 100 nm simple and PEGylated liposomes. For the dilutions of 1:125, 
1:50, 1:20, and 1:10, DLS gave a mean diameter of 161.77 ± 13.8 nm, 145.03 ± 9.2 
nm, 135.6 ± 4.75 nm and 127.1 ± 6.32 nm respectively. 
 Figure 3.30: The graph shows the average diameter of 100 nm PINPs at different dilutions, as 
determined by DLS. A variety of values (mean ± SD, n=3) were observed at the different liposome 
dilution with the most accurate values (135.6 and 127.1 nm) at dilutions of 1:20 and 1:10. However, all 
values were slightly larger than the anticipated. 
 
50 nm PINPs 
In the case of 50 nm PINPs the different dilutions of 1:125, 1:50, 1:20, 1:10 gave 
mean diameters of 86.92 ± 5.13 nm, 92.65 ± 5.73 nm, 83.26 ± 12.25 nm and 78.57 ± 


























Figure 3.31: The graph shows the average sizes of 50 nm PINPs at different dilutions as determined 
by DLS. A variety of values (mean ± SD, n=3) was observed at the different liposome dilutions with the 
most accurate value (78.57 nm) obtained at a dilution of 1:10. However, all values were slightly larger 
than the anticipated. 
 
Stability assay for PINPs 
A stability assay for PINPs was also carried out in order to test if the presence 
of the peptide inhibitor on the surface of the liposomes could affect their size 
stability by DLS. The three different sizes of PINPs were examined for two months at 
4°C. The liposome suspensions were measured every 10 days and for this stability 
test the same dilution of 1:20 was used throughout. The PINPs showed higher values 
using DLS compared to simple and PEGylated liposomes, and their polydispersity 
values were also greater. As can be seen from figure 3.32, the size measurements of 
PINPs were not as stable and reproducible as those of simple and PEGylated 
liposomes. Consequently, comparing the three stability assays for the three different 






























measurements. A possible explanation of what happens with PINPs at different 
dilutions is given in the diagram below (see figure 3.33). Due to the fact that peptide 
inhibitor RI-OR2-TAT, and specifically the TAT region of the peptide has a high 
positive charge, this may affect the electrical conductivity of the liquid and so create 
a larger hydrodynamic diameter (Rh) than the simpler liposomes, and this is detected 
and measured by DLS instead of the normal hydrodynamic diameter. 
Figure 3.32: The graph shows a stability test of the three different sizes of PINPs for 2 months using 
dilution of 1:500 at 4°C. The three different sizes of PINPs gave variety of values during the two 













Figure 3.33: Hydrodynamic diameter. This diagram indicates how the electrical charge of a PINP can 
affect the measurement of its size using DLS and TEM. DLS, measures the hydrodynamic diameter (Rh) 
of the nanoparticle and as result would be anticipated to give a larger value than with TEM which 
measures the physical diameter. 
Conclusion (using Dynamic Light Scattering DLS) 
DLS was one of the techniques used in this project in order to characterize and 
compare the sizes of the three types of liposomes.  As can be observed from the data 
above, DLS proved to be a rapid and easy technique for the measurement of wet 
nanoparticles with diameters of 200 nm or less. Furthermore, as the three different 
types of liposomes gave varying size measurements at different concentrations it was 
shown that concentration is an important factor which can affect the measurement 
of the diameter of nanoliposomes. It is important to mention that in order to obtain 
the above results I carried out many measurements of the liposomes suspensions, as 
the values from DLS varied each time. In addition, the presence of the PEG molecule 
and the peptide on the surface of the liposomes resulted in slight changes in 
diameter compared with simple liposomes. However, DLS does not give any direct 
information on the shape and morphology of the liposomes, and so further 
examination of the ultrastructure of liposomes was carried out using Transmission 
Electron Microscope (TEM). 
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CHAPTER FOUR - TEM RESULTS 
4.1 Ultrastructural characterization of liposomes by size and shape using 
Transmission Electron Microscope (TEM) 
In this chapter the morphology and the size of the three types of NLPs was 
investigated using a powerful imaging technology, TEM. TEM cannot reveal any 
chemical or behavioral differences between plain, MAL-PEG and PINP liposomes, but 
is able to characterize them by their size and shape. 
4.1.1 Morphology and ultrastructure of simple liposomes 
The samples underwent negative staining (liposomes in filtered PBS) and were 
examined under TEM by Dr. Nigel Fullwood. Negative staining is a fast and relatively 
easy procedure. The ultrastructure of different types of liposomes using TEM can 
reveal not only their shape, but also their lamellarity which is an important aspect of 
their structure and consequent properties. So, in order to evaluate the importance of 
a freeze and thaw process and bath sonication method during the preparation of 
liposomes (by the thin film method) and how this can affect their lamellarity we 
prepared samples in which both of these the two techniques were applied, and some 
samples without. According to the negative staining micrographs, the majority of 
simple liposomes of different sizes, prepared without freeze-thaw and sonication 
processes have a multilamellar structure (e.g. see figure 4.3). Initially, the TEM 
samples were prepared using 5 mM liposomes (total lipid content), but as can be 
seen in some images (figures 4.1 and 4.3) these liposomes were much too 
concentrated and could not be examined properly. Subsequent samples used a less 
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concentrated suspension of liposomes (1 mM) to avoid their dense accumulation. 
However, even though a lower concentration of liposomes was used, under the TEM, 
the liposomes were still seen to congregate in large clumps.  In addition, some of 
them have a typical ring shape (unilamellar) (see figure 4.2) but the majority of them 
gave an unstable shape with an onion layer (multilamellar) (see figure 4.3) structure.  
100 nm simple liposomes  
The following negative staining micrographs represent simple liposomes of 100 
nm diameter which did not use a freeze and thaw process and bath sonication during 
their preparation. As can be observed from the micrographs, the majority of these 
liposomes have an irregular shape and almost all of them are multilamellar vesicles 







Figure 4.1: 100 nm simple liposomes in filtered PBS at 5 mM. The negative staining micrograph 
shows a sample of 100 nm simple liposomes. The liposomes can be seen as being rounded in shape but 











Figure 4.2:  100 nm simple liposome in filtered PBS. The negative staining micrograph shows a 
sample of 100 nm simple liposomes. This single liposome can clearly be seen as being rounded in 








Figure 4.3:  100 nm simple liposome in filtered PBS at 5 mM. The negative staining micrograph shows 
a sample of 100 nm simple liposomes. The liposomes can clearly be seen as being rounded in shape but 
the majority of them are multilamellar structures (onion structure). Scale bar = 50 nm. 
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50 nm simple liposomes  
The following negative staining micrographs represent simple liposomes of 50- 
nm diameter which were not subjected to the freeze and thaw process and bath 
sonication during their preparation. As can be seen from the images below, the 
liposomes present an irregular shape and they form clumps (see figure 4.4). The 
images were taken at low magnification in order to see how the liposomes are 








Figure 4.4: 50 nm simple liposomes in filtered PBS at 1 mM: The negative staining micrograph shows 
a sample of 50 nm simple liposomes. The liposomes can clearly be seen as being rounded in shape with 






4.1.2 Morphology and ultrastructure of PEGylated liposomes using TEM 
100 nm PEGylated liposomes  
The following negative staining micrographs represent PEGylated liposomes of 
100 nm diameter which were not subjected to a freeze and thaw process and bath 
sonication during their preparation. As can be observed from the micrographs below, 
the majority of liposomes have an irregular shape and almost all of them have 








Figure 4.5: 100 nm PEGylated liposomes in filtered PBS at 1 mM. The negative staining micrograph 
shows a sample of 100 nm PEGylated liposomes. The micrograph shows a heterogeneous population 
of vesicles which have a distorted shape and vary in size. The majority of them have multilamellar 









Figure 4.6: 100 nm PEGylated liposomes in filtered PBS at 1 mM. The negative staining micrograph 
shows a sample of 100 nm PEGylated liposomes. The liposomes can clearly be seen as being rounded in 
shape (see arrows) but the majority of them are multilamellar structures (onion layer structure).The 








Figure 4.7: 100 nm PEGylated liposomes in filtered PBS at 1 mM. The negative staining micrograph 
shows a sample of 100 nm PEGylated liposomes in filtered PBS. The micrograph shows a 










Figure 4.8: 100 nm PEGylated liposomes in filtered PBS at 1 mM. The negative staining micrograph 
shows a sample of 100 nm PEGylated liposomes at high magnification. The liposomes were clustered 








Figure 4.9: 100 nm PEGylated liposomes in filtered PBS at 2.5 mM. The negative staining micrograph 
shows a concentrated sample (2.5 mM) of 100 nm PEGylated liposomes. The liposomes can clearly be 
seen as being rounded in shape. The micrograph shows a heterogeneous population of vesicles which 
have a distorted shape and vary in size Scale bar = 100 nm. 
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4.1.3 Morphology and ultrastructure of PINPs using TEM 
200 nm PINPs  
For vesicles larger than 100 nm in diameter, the procedures of freeze and thaw 
and bath sonication are not recommended because this will decrease their diameter, 
something that must be avoided in this case. So, in this case, the samples of 200 nm 
liposomes were prepared without either of these two procedures. The following 
negative staining micrographs represent a heterogeneous population of PINPs with 








Figure 4.10: 200 nm PINPs in filtered PBS at 1 mM. The negative staining micrograph shows a sample 













Figure 4.11: 200 nm PINPs in filtered PBS at 1 mM. The negative staining micrograph shows a sample 
of 200 nm PINPs diluted in filtered PBS. The liposomes can clearly be seen as being rounded in shape 
while a heterogeneous mixture of PINPs with a diameter range of 100-200 nm was observed (see 
arrows). Scale bar = 100 nm. 
 
100 nm PINPs 
The following negative staining micrographs represent PINPs of 100 nm which 
were subjected to a freeze and thaw process and bath sonication during their 
preparation. As can be observed from the micrographs below, the majority of these 
liposomes have a more stable and rounded shape, close to their expected size (100- 
nm) and they now have a unilamellar structure. In addition, in the following negative 
staining micrographs (see figures 4.12 and 4.13) some of the liposomes were stained 











Figure 4.12: 100 nm PINPs in filtered PBS at 1 mM. The negative staining micrograph shows a sample 
of 100- nm PINPs. The liposomes can clearly be seen as being rounded in shape and they vary only 







Figure 4.13: 100 nm PINPs in filtered PBS at 1 mM. The negative staining micrograph shows a sample 
of 100 nm PINPs. The liposomes were clustered together creating clumps. The red arrow shows a 
liposome with positive staining while the black arrow shows a liposome with negative staining. The 




50 nm PINPs 
The following negative staining micrographs represent a sample of 50 nm PINPs 
where the freeze and thaw process using liquid nitrogen and bath sonication was 
applied during their preparation. As can be seen, these two methods are responsible 
for the transformation of multilamellar vesicles to unilamellar (single layer) vesicles. 
As can be observed from the micrographs below (see figures 4.14 - 4.17), most of 








Figure 4.14: 50 nm PINPs in filtered PBS at 1 mM. Here the PINPs were prepared with freeze-thawing 
and bath sonication. The negative staining micrograph shows a sample of 50 nm PINPs liposomes at 











Figure 4.15: 50 nm PINPs in filtered PBS at 1 mM.  The negative staining micrograph shows a sample 
of 50 nm PINPs. While a heterogeneous mixture of PINPs with a diameter range of ~ 30-130 nm was 









Figure 4.16: 50 nm PINPs in filtered PBS at 1 mM.  The negative staining micrograph shows a sample 
of 50 nm PINPs. A heterogeneous heterogeneous mixture of PINPs with a diameter range of 50-130 nm 










Figure 4.17: 50 nm PINPs in filtered PBS at 1 mM.  The negative staining micrograph shows a sample 
of 50 nm PINPs at high magnification. The liposomes can be seen clearly as rounded in shape with 
unilamellar structures while a heterogeneous mixture of PINPs was observed. The different diameters 
of liposomes are shown using different colours of lines (yellow, green, blue, orange and red). Scale bar 
= 100 nm. 
 
Conclusion using TEM 
TEM was the second technique which was used for the characterization of 
liposomes. It is important to note that the current study is based on the production 
of liposomes using the lipid thin film method, and variations in this method can 
greatly affect their characteristics. Some of these characteristics, notably liposome 
morphology and ultrastructure, including lamellarity (production of unilamellar or 
multilamellar vesicles), are not revealed by DLS, but could be determined here by 
using TEM. In addition, another characteristic of liposomes which cannot be revealed 
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by DLS, but is revealed by TEM, is how the liposomes are arranged in space. We 
found that the shape, size range, degree of clumping, and lamellarity of the 
liposomes are all affected by the preparation technique. This is not surprising, 
because it has already been well established that, the preparation of liposomes, their 
environment can greatly affect these characteristics. Often, during the preparation of 
liposomes, their free enthalpy is not stable, and as a result this creates liposomes 
which can change in size, shape and lamellarity with time (Chetanachan et al., 2008; 
Ran and Yalkowsky 2003; Zasadzinski, 1986). In particular, the lamellarity of, 
liposomes preparation is very important, and is impossible to examine by DLS. In 
order to produce unilamellar liposomes, which are a prerequisite for the production 
of PINPs, it is essential, based on the TEM results presented here, to include the 












CHAPTER FIVE – CELL TOXICITY AND CELL PENETRATION RESULTS 
5.1. Cell toxicity using the three different types of liposomes 
After the characterization of liposomes based on their size and shape, NLs 
were also characterized based on their toxicity to neuroblastoma cells because for a 
drug delivery system it is obviously important to be non-toxic. In order to examine 
the toxicity of the three types of liposomes (simple, PEGylated liposomes and PINPs), 
at three distinct sizes of 200 nm, 100 nm and 50 nm, a MTS cell toxicity assay was 
performed. Here, these different liposomes were tested for their toxicity effects on 
SHSY-5Y neuroblastoma cells grown in culture, using each type of liposome at four 
different concentrations (50 μM, 10 μM, 1 μM and 0.1 μM). 
5.1.1 Simple liposomes 
In the case of simple liposomes, as can be observed from figures 5.1 and 5.2, 
there was no loss in the viability of neuroblastoma cells at any of the four different 
concentrations (50 μM, 10 μM, 1 μM and 0.1 μM), with liposomes in DMEM, giving 
almost the same absorbance (measure of viability) as control cells with no liposomes 
(represented by the dark red coloured bar to the left of the graph), after 24 h 
incubation at 37°C. This experiment was performed twice and the results for both 
































































Figure 5.1: Simple liposomes are not toxic to cells. The graph shows a MTS cell viability assay (mean 
±SD, n=4) of SHSY-5Y neuroblastoma cells grown in the presence of three different sizes of simple 
liposomes at different concentrations (0.1, 1, 10 μΜ) for 24 h. The bars with star (all) are not 
statistically significant from the untreated cells. *=P>0.05 by Student’s t-test. 
Figure 5.2: Simple liposomes are not toxic to cells. The graph shows a MTS cell viability assay of SHSY-
5Y neuroblastoma cells (mean ± SD, n=4) grown in the presence of three different sizes of simple 
liposomes at different concentrations (1, 10, 50 μΜ) for 24 h. The bars with star (all) are not 

































5.1.2 PEGylated liposomes and PINPs 
In the case of PEGylated liposomes and PINPs, exactly the same experiments 
with SHSY-5Y neuroblastoma cells were carried out as for the simple liposomes, and 
they also did not affect the viability of these cells. It can be concluded that neither 
the MAL-PEG liposomes nor PINPs are toxic towards SHSY-5Y neuroblastoma cells, 
despite the presence of the MAL-PEG molecule on their surface (for PEGylated 
liposomes) and the presence of RI-OR2-TAT peptide (in the case of PINPs). As can be 
seen from figures 5.3 to 5.6, the different concentrations of PEGylated liposomes and 
PINPs, after exposure to SHSY-5Y neuroblastoma cells for 24 h, produced no loss in 
viability of the cells. The red bar to the left of the graphs represents the viability of 
control cells without liposomes, and the blue bars represent the different 
concentrations of liposomes. The viability of untreated cells compared to cells 
incubated with liposomes was approximately the same.  
Figure 5.3: PEGylated liposomes are not toxic to cells. The graph shows a MTS cell viability assay 
(mean ±SD, n=4) of SHSY-5Y neuroblastoma cells grown in the presence of three different sizes of 
































































Figure 5.4: PEGylated liposomes are not toxic to cells. The graph shows a MTS cell viability assay 
(mean ±SD, n=4) of SHSY-5Y neuroblastoma cells grown in the presence of three different sizes of 
PEGylated liposomes at different concentrations (1, 10, 50 μΜ) for 24 h. Only the bar with star is 
statistically significant from untreated cells. *=p<0.05 by Student’s t-test. 
Figure 5.5: PINPs are not toxic to cells. The graph shows a MTS cell viability assay (mean ±SD, n=4) of 
SHSY-5Y neuroblastoma cells grown in the presence of three different sizes of PINPs at different 
concentrations (0.1, 1, 10 μΜ) for 24 h. The bars with star (all) are not statistically significant from 






























Figure 5.6: PINPs are not toxic to cells. The graph shows a MTS cell viability assay (mean ±SD, n=4) of 
SHSY-5Y neuroblastoma cells grown in the presence of three different sizes of PINPs at different 
concentrations (1, 10, 50 μΜ) for 24 h. The bars with star only are statistically significant from 
untreated cells. *=p<0.05 by Student’s t-test. 
 
5.2 Statistical analysis of cell viability results using T-test 
A statistical analysis of the above cell viability data using the Student t-test was 
carried out in order to confirm that the liposomes were not toxic towards SHSY-5Y 
neuroblastoma cells (null hypothesis). T-test is used to determine if two sets of data 
(the untreated cells and the different concentrations of different types of liposomes) 
are significantly different from one another. The t-test analysis is shown in the tables 
below. Also, the significant values are higher than controls - i.e. more healthy.  This is 
probably because we are supplying them with lipids, which acts as an addition 'food 
source'. 
 
Key for tables with T-tests 
P value (Probability) = 0.05                *If T-test > 0.05  NO significant difference 



















0.1 0.74 NO 0.25 NO 0.52 NO 
1 0.94 NO 0.6 NO 0.5 NO 
10 0.59 NO 0.055 NO 0.068 NO 
50 0.81 NO 0.162 NO 0.17 NO 
Table 5.1: Different concentrations of simple liposomes Vs untreated cells. This table shows an 
analysis of simple liposomes of three different sizes (200, 100 and 50 nm) and different concentrations 
(0.1, 1, 10 and 50 μΜ) comparing them with the untreated cells according to the Student t-test (P 
value). None of the differences between treated and control cells are statistically significant (P>0.05).  















0.1 0.39 NO 0.6 NO 0.58 NO 
1 0.39 NO 0.98 NO 0.8 NO 
10 0.65 NO 0.81 NO 0.69 NO 
50 0.02 YES 0.088 NO 0.61 NO 
Table 5.2: Different concentrations of PEGylated liposomes Vs untreated cells. This table shows an 
analysis of PEGylated liposomes of three different sizes (200, 100 and 50 nm) and different 
concentrations (0.1, 1, 10 and 50 μΜ) compared with untreated cells, according to the Student t-test (P 
value). None of the differences between treated and control cells are statistically significant (P>0.05) 
except for the 200 nm PEGylated liposomes (50 μM) which gave a higher MTS cell viability value 
(P<0.05) than untreated cells. 


















0.1 0.72 NO 0.74 NO 0.93 NO 
1 0.04 YES 0.064 NO 0.29 NO 
10 0.055 NO 0.43 NO 0.46 NO 
50 0.18 NO 0.0077 YES 0.98 NO 
Table 5.3: Different concentrations of PINPs Vs untreated cells. This table shows an analysis of PINPs 
of three different sizes (200, 100 and 50 nm) and different concentrations (0.1, 1, 10 and 50 μΜ) 
compared with untreated cells, according to the Student t-test (P value). None of the differences 
between treated and control cells are statistically significant (P>0.05), except for the200 nm and 50 nm 
PINPs (1 and 50 μΜ) which gave a higher MTS cell viability value (P<0.05) than untreated cells. 
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5.3 Ability of liposomes to rescue SHSY-5Y cells in the presence of Aβ 
In addition, using the MTS assay, the three different types of liposomes were 
examined in order to test for their ability to rescue SHSY-5Y cells from the toxic effect 
of Aβ, which was pre-aggregated for 24 h. The SHSY-5Y cells were exposed to 5 μM 
Aβ and using several concentrations of the three types of liposomes we examine 
their ability to block the toxic effects of Aβ. The first column to the left (control – no 
Aβ) in figures 5.7 and 5.8 shows data for cells which were not exposed to Aβ, i.e. the 
viability of healthy SHSY-5Y cells, while the red bar represents the negative effect on 
cell viability of the presence of 5 µM Aβ. As can be seen from the graphs, the viability 
of the Aβ-treated cells was decreased by approximately 36% in relation to the heathy 
control value. 
 
5.3.1 Simple and PEGylated liposomes 
Figures 5.7 and 5.8 show cell viability data for effects of the three different 
sizes of simple and PEGylated liposomes on SHSY-5Y cells which were exposed to 
5 μM Aβ at three different concentrations of liposomes (0.1, 1, 10 μM). Both types of 
liposomes were unable to rescue the cells from the toxicity of Aβ, but were 
themselves not toxic to the cells. For both types of liposomes, the MTS values 
obtained for all three sizes of liposomes were very close to the red bar, which 
































Cells exposed to 5 μM Aβ42 and PEGylated liposomes in three 
different sizes at the above concentrations






































Cells exposed to 5 μM Aβ42 and simple liposomes in three 
different sizes at the above concentrations













Figure 5.7: Simple liposomes cannot block the toxic effect of Aβ. The graph shows the inability of 
simple liposomes of three different sizes and concentrations (0.1, 1, 10 μΜ) to rescue SHSY-5Y 
neuroblastoma cells from the toxic effect of 5 μΜ of pre-aggregated Aβ. Only the bar with star is 
statistically significant from cells with Aβ. *=p<0.05 by Student’s t-test. 
 
Figure 5.8: PEGylated liposomes cannot block the toxic effect of Aβ. The graph shows the inability of 
PEGylated liposomes of three different sizes and concentrations (0.1, 1, 10 μΜ) to rescue SHSY-5Y 
neuroblastoma cells from the toxic effect of 5 μΜ of pre-aggregated Aβ. The bars with star (all) are not 































Cells exposed to 5 μM Aβ42 and PINPs in three different sizes   
at the above concentrations







According to the graph below (figure 5.9), all concentrations and sizes of PINPs 
were able to rescue the SHSY-5Y cells from the toxic effect of Aβ. The three different 
concentrations of PINPs of all sizes maintain the viability of the cells to almost the 
same value as the control cells with no Aβ. As the concentration of PINPs is 
increased, the amount of rescued cells increased as well, while at the lower 
concentrations of PINPs, the amount of viable cells is lower. 
Figure 5.9: PINPs block the toxic effect of Aβ. The graph shows the ability of PINPs of three different 
sizes and concentrations (0.1, 1, 10 μΜ) to rescue SHSY-5Y neuroblastoma cells from the toxic effect of 
5 μΜ of pre-aggregated Aβ. The bars with star are statistically significant from cells with Aβ. *=P<0.05 






5.4 Statistical analysis of the ability of liposomes to rescue SHSY-5Y cells in the 
presence of Aβ using T-test 
As above, a statistical Student t-test was carried out in order to confirm that 
both, simple and PEGylated liposomes were unable to block the toxic effect of Aβ, 
while PINPs were able (null hypothesis). The tables below (table 5.4-5.6) represent 
the statistical analysis of the ability of the three types of liposomes to rescue SHSY-5Y 
cells in the presence of Aβ using Student t-test. 















0.1 0.64 NO 0.95 NO 0.5 NO 
1 0.23 NO 0.096 NO 0.051 NO 
10 0.25 NO 0.36 NO 0.02 YES 
Table 5.4: Different concentrations of simple liposomes Vs cells exposed to Aβ. This table shows an 
analysis of simple liposomes of three different sizes (200, 100 and 50 nm) and different concentrations 
(0.1, 1 and 10 μΜ) comparing them with the cells exposed to Aβ according to the Student t-test (P 
value). None of the differences between cells exposed to Aβ and cells exposed to simple liposomes are 
statistically significant (P>0.05), except for the 50 nm simple liposomes (10 μΜ) which gave a higher 
MTS value (P<0.05) than cells exposed to Aβ. 















0.1 0.62 NO 0.065 NO 0.26 NO 
1 0.95 NO 0.135 NO 0.21 NO 
10 0.3 NO 0.4 NO 0.28 NO 
Table 5.5: Different concentrations of PEGylated liposomes Vs cells exposed to Aβ. This table shows 
an analysis of PEGylated liposomes of three different sizes (200, 100 and 50 nm) and different 
concentrations (0.1, 1 and 10 μΜ) comparing them with the cells exposed to Aβ according to the 
Student t-test (P value). None of the differences between cells exposed to Aβ and cells exposed to 



















0.1 0.0065 YES 0.0005 YES 0.0075 YES 
1 0.0038 YES 0.00051 YES 0.00013 YES 
10 1.64E-05 YES 1.22E-05 YES 1.44E-05 YES 
Table 5.6: Different concentrations of PINPs Vs cells exposed to Aβ. This table shows an analysis of 
PINPs of three different sizes (200, 100 and 50 nm) and different concentrations (0.1, 1 and 10 μΜ) 
comparing them with the cells exposed to Aβ according to the Student t-test (P value). All of the 
differences between cells exposed to Aβ and cells exposed to PINPs are statistically significant 
(P<0.05). 
 
5.5 Conclusion applying cell toxicity assay (MTS) 
The use of the MTS assay to measure cell toxicity was divided in two 
experiments: (a) to test whether the liposomes were toxic to SHSY-5Y neuroblastoma 
cells, and (b) to examine the ability of the three types of liposomes to affect Aβ 
aggregation and protect against Aβ cytotoxicity. Both of them revealed important 
information for the three types of NPs. First of all, according to the results for part A, 
we can conclude that the three types of liposomes are not toxic towards SHSY-5Y 
cells at the concentrations tested, which is positive in terms of the requirements for 
development of a non-toxic drug (PINPs). These results confirm the fact that the 
lipids themselves are not toxic, which is anticipated given that they are basic 
components of the membranes of cells. Based on part B, the results revealed that 
both simple and PEGylated liposomes were not able to rescue the SHSY-5Y cells from 
Aβ cytotoxicity, while the presence of PINPs resulted in rescue of the cells,  even at 
low PINP concentrations (0.1 μM). 
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5.6 Cell penetration assay – Fluorescent microscopy using 200 nm of PEGylated 
liposomes and PINPs  
Based on previous studies, the site where Aβ is generated is not clear, but 
Takahashi et al. (2002) have determined that compartments called ‘multivesicular 
bodies’ are responsible for the release of proteins from the interior side of the cell to 
the exterior side. Also, there is some evidence that Aβ aggregation begins inside 
cells, suggesting that the prevention of intracellular aggregation of Aβ is a feasible 
target for drug development. For this to happen, the drug must be able to penetrate 
into the cells and inhibit Aβ aggregation or prevent its release from the inside to the 
outside of the cell. It is believed that the inhibition of Aβ accumulation is easier 
inside the cell instead rather than after its release to the exterior (Takahashi et al., 
2002). It is also necessary to find a way to get the drug from the bloodstream across 
the BBB (the BBB is a layer of cells with tight junctions between them that prevents 
access of many molecules to the brain). In the following assay, 200 nm fluorescent 
bodipy PEGylated liposomes and PINPs (emission wavelength 507 nm and excitation 
wavelength 495 nm) at different concentrations (0.1 μM, 1 μM and 10 μM) were 
incubated in standard mammalian cell culture conditions with SHSY-5Y 
neuroblastoma cells for an hour and their ability to penetrate into cells was 
investigated using a confocal microscope (LSM 510 – Laser Module – ZEISS). 
According to the fluorescent images below, as the concentration of fluorescent 
bodipy PINPs or PEGylated liposomes was increased, so the amount of green 
fluorescence also increased, which is an indication that more PINPs or PEGylated 
liposomes have penetrated into the cells. In the figure 5.10, which represents a 
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sample with neuroblastoma cells only, we did not expect to observe green 
fluorescence (no bodipy liposomes) but in some cases the cells appear to produce a 
signal due to auto-fluorescent properties of the cells themselves. 
Figure 5.10: A confocal image of SHSY-5Y cells grown on glass coverslips with filtered PBS and 
incubated for an hour (Control). Panels A, B and C present the same section of a slide, under different 
filters. A: The green fluorescent colour emitted by the cells themselves is due to auto-fluorescence. B: 
DAPI-staining – 405 nm DNA (blue) - in the nucleus of SHSY-5Y cells. C: Merging of both images (A+B) 
shows the blue colour (nucleus of cells) together with green auto-fluorescence. Scale bar = 20 μΜ. 
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Figure 5.11: A confocal image of SHSY-5Y cells grown on glass coverslips and incubated for an hour 
with fluorescent (bodipy) PINPs at 0.1 μM. Panels A, B and C present the same section of a slide, 
under different filters. A: Alexa-fluor-488 nm shows that PINPs have penetrated the membranes of 
SHSY-5Y cells (green). B: DAPI-stained – 405 nm DNA (blue) - nucleus of SHSY-5Y cells. C: Merging of 
both images (A+B) shows the nucleus of cells (blue) and the fluorescent PINPs (green). The intensity of 
the green fluorescent colour is increased in relation to the control sample, which is an indication that 





Figure 5.12: A confocal image of SHSY-5Y cells grown on glass coverslips and incubated for an hour 
with fluorescent (bodipy) PINPs at 1 μM. Panels A, B and C present the same section of a slide, under 
different filters. A: Alexa-fluor-488 nm shows that PINPs have penetrated the membranes of SHSY-5Y 
cells (green). B: DAPI-stained – 405 nm DNA (blue) - nucleus of SHSY-5Y cells. C: Merging of both 
images (A+B) shows the nucleus of cells (blue) and the fluorescent PINPs (green). The intensity of the 
green fluorescence is increased in relation to 0.1 μM of PINPs, showing that more of the PINPs at a 




Figure 5.13: A confocal image of SHSY-5Y cells grown on glass coverslips and incubated for an hour 
with fluorescent (bodipy) PINPs at 10 μM. Panels A, B and C present the same section of a slide, under 
different filters. A: Alexa-fluor-488 nm shows that PINPs have penetrated the membranes of SHSY-5Y 
cells (green). B: DAPI-stained – 405 nm DNA (blue) - nucleus of SHSY-5Y cells. C: Merging of both 
images (A+B) shows the nucleus of cells (blue) and the fluorescent PINPs (green). The intensity of the 
green fluorescence is increased in relation to 1 μM of PINPs, showing that even more of the PINPs at a 





Figure 5.14: A confocal image of SHSY-5Y cells grown on glass coverslips and incubated for an hour 
with fluorescent (bodipy) PEGylated liposomes at 0.1 μM. Panels A, B and C present the same section 
of a slide, under different filters. A: Alexa-fluor-488 nm shows the PEGylated liposomes which 
penetrated the membrane of SHSY-5Y cells (green). B: DAPI-stained – 405 nm DNA (blue) - nucleus of 
SHSY-5Y cells. C: Merging of both images (A+B) shows the nucleus of cells (blue) and the fluorescent 
PEGylated liposomes (green). The intensity of the green fluorescent colour is increased in relation to 
the control sample which is an indication that PEGylated liposomes at the concentration of 0.1 μM are 





Figure 5.15: A confocal image of neuroblastoma SHSY-5Y cells grown on glass coverslips and 
incubated for an hour with fluorescent (bodipy) PEGylated liposomes at 1 μM. Panels A, B and C 
present the same part of a slide, under different filters. A: Alexa-fluor-488 nm shows the PEGylated 
liposomes which have penetrated the membrane of SHSY-5Y cells (green). B: DAPI-stained – 405 nm 
DNA (blue) - nucleus of SHSY-5Y cells. C: Merging of both images (A+B) shows the nucleus of cells (blue) 
and the fluorescent PEGylated liposomes (green). The intensity of the green fluorescent colour is 
increased in relation to 0.1 μM PEGylated liposomes, which is an indication that more of the PEGylated 





Figure 5.16: A confocal image of SHSY-5Y cells grown on glass coverslips with fluorescent (bodipy) 
and incubated for an hour with PEGylated liposomes at 10 μM. Panels A, B and C present the same 
section of a slide, under different filters. A: Alexa-fluor-488 nm shows the PEGylated liposomes which 
have penetrated the membrane of SHSY-5Y cells (green). B: DAPI-stained – 405 nm DNA (blue) - 
nucleus of SHSY-5Y cells. C: Merging of both images (A+B) shows the nucleus of cells (blue) and the 
fluorescent PEGylated liposomes (green). The intensity of green fluorescent colour increased in relation 
to 1 μM of PEGylated liposomes, which is an indication that more PEGylated liposomes at the 





Figure 5.17: Neuroblastoma SHSY-5Y cells grown on glass coverslips with fluorescent (bodipy) at 
different concentrations of PINPs and PEGylated liposomes. A-C micrographs show confocal images 
of SHSY-5Y cells incubated with PINPs at different concentrations for 1 h, while D-F micrographs show 
confocal images of SHSY-5Y cells incubated with PEGylated liposomes at different concentrations for 
1 h. Comparing the same concentrations of the two types of liposomes (PINPs and PEGylated) (i.e. 
compare A with D; B with E; and C with F) we can observe that both types of liposomes are able to 









5.6.1 Conclusion cell penetration assay 
The cell penetration assay was an experimental procedure which was carried 
out in order to examine the ability of our drug (PINPs) to penetrate into 
neuroblastoma SHSY-5Y cells. The results were positive: the successful penetration of 
PINPs into the cells is shown from the figures above. However, under the same 
conditions we found out that the PEGylated liposomes (even in the absence of the 
cell penetrating ‘TAT’ sequence of RI-OR2-TAT) have some ability to penetrate into 
neuroblastoma cells. According to a previous study (Parthsarathy et al., 2013), two 
types of the peptide inhibitors Flu-RI-OR2-TAT and Flu-RI-OR2 were tested for their 
ability to enter cultured SHSY-5Y cells, and the results revealed that only Flu-RI-OR2-
TAT was able to penetrate the cells.  
However, in the current thesis we examined both fluorescent PINPs and 
PEGylated liposomes to see if they were able to enter the cultured SHSY-5Y cells, and 
our results have revealed that both types of liposomes have the ability to penetrate 
into these cells (see figures above). This is another indication of how potent the 
liposomes themselves are as a drug delivery system, without any peptide attached 
on their surface to be taken up by the cells. For this reason further experiments are 
required to confirm the mechanism of how liposomes are taken up by 
neuroblastoma cells. However, we can conclude that the conjugation of the peptide 
inhibitor onto the surface of PEGylated liposomes has resulted in the creation of a 




Figure 5.18: Cell penetration. This illustration shows the ability of different versions of the peptide 
inhibitor and PEGylated liposomes to enter SHSY-5Y neuroblastoma cells. The left part (A) of the figure 
represents an experiment which compares the ability of Flu-RI-OR2-TAT and Flu-RI-OR2 to penetrate 
the cultured cells. Due to the presence of the TAT sequence attached to the peptide, Flu-RI-OR2-TAT is 
able to enter cells, while Flu-RI-OR2 is not. The right part (B) of the figure represents an experiment 
which compares the ability of fluorescent PINPs and fluorescent PEGylated liposomes to enter the cells. 
In this case both types of liposomes can penetrate the cells, but the PINPs do so with enhanced 
efficiency because of the presence of the TAT transit sequence. However, fluorescent PEGylated 









5.7 PINPs are potent aggregation inhibitors (Th-T assay) 
A Th-T assay was used in order to determine if PINPs can block or inhibit the 
aggregation of Aβ. In the following figures, Th-T data are presented for Aβ42 
incubated for approximately two days with various molar ratios of PEGylated 
liposomes and PINPs (total lipids): Aβ, ranging from 1:1 to 1:100. In the case of 
PEGylated liposomes the assay was stopped after 37 h instead of 48 h because the 
readings had reached a steady state. In these Th-T assays, we did not get the 
expected results. We (our team) tried the current experiment with PINPs from our 
collaborators in Italy and with PINPs which were prepared in our laboratory more 
than 5 times and we did not manage to get the expected results (see figures 5.19-
5.22) for some reasons.  The reasons for this are not clear, but could include the fact 
that amyloid aggregation experiments employing the Th-T assay are very variable, 
and if the nanoliposomes (PINPs) are not mixed well with Aβ and Th-T this can give a 
poor result. However, the PINPs did show some inhibition of aggregation of Aβ, 
comparing with the PEGylated liposomes which did not have any effect (see figure 
5.22).  
According to Gregori et al., 2015 (manuscript submitted) carried out the same 
experiment and they revealed that 50% inhibition occurs at around a 1:50 molar 
ratio of lipid to Aβ1-42 or, as the inhibitory peptide is only ~2.5% of total lipids, 
~1:2000 of RI-OR2-TAT to Aβ1-42. On the other hand, PEGylated liposomes were also 
tested for their ability to inhibit the Aβ aggregation at higher ratios (1:1 and 1:2) but 































Figure 5.19: The graph shows a time course of Aβ-42 aggregation in the presence of PEGylated 
liposomes with various ratios incubated for 37 h. None of the dilutions showed any inhibition of Aβ 
aggregation. So the PEGylated liposomes are not considered suitable for the inhibition of Aβ 
aggregation. 
Figure 5.20: PEGylated liposomes do not inhibit the aggregation of Aβ42. This graph represents Th-T 
data for Aβ42 with various molar ratios of PEGylated liposomes for 37 h incubation: “Background” is 
buffer only, “Aβ” (red bar) is Aβ42 incubated at 25 μΜ for 37 h without inhibitor, the blue bars 
represent the different concentrations of PEGylated liposomes (1 to 1 = 25 μΜ) which were incubated 
with Aβ42 for 37 h and the black bar is PEGylated liposomes only with no Aβ. The bars with star only 
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Figure 5.21: The graph shows a time course of Aβ-42 aggregation in the presence of PINPs with 
various ratios incubated for 48 h. The dilutions 1 to 1 up to 1 to 10 showed important inhibition of Aβ 
aggregation and dilutions 1 to 50 and 1 to 100 showed slight inhibition. Therefore, more diluted 
samples of PINPs (1 to 500 and 1 to 1000) did not show any inhibition of Aβ aggregation (date not 
shown). 
Figure 5.22: PINPs inhibit the aggregation of Aβ42. This graph represents Th-T data for Aβ42 with 
various molar ratios of PINPs for 48 h incubation: “Background” (orange bar) is buffer only, “PINPs 
only” are PINPs only without Aβ, “Aβ” (red bar) is Aβ42 incubated at 25 μΜ for 48 h without inhibitor, 
the blue bars represent the different concentrations of PINPs (1 to 1 = 25 μΜ) which are incubated with 
Aβ42 for 48 h. The bars with star only are statistically significant from Aβ. *=p<0.05 by Student’s t-test. 
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CHAPTER SIX - DISCUSSION 
6.1 Background 
AD is the most common neurodegenerative disease and is characterized by the 
accumulation of senile plaques, containing fibrils composed of the protein Aβ, and 
neurofibrillary tangles made of the protein Tau (Blennow et al., 2006). It is estimated 
that around 1 in 3 people will have this condition by the end of their life, and this is a 
problem that will become even more common with the growing ageing population. 
Many scientists have tried to develop new drugs to treat this fatal neurodegenerative 
disease. Recent studies have indicated that the retro-inverso peptide ‘RI-OR2-TAT’ 
could be a successful treatment for AD, with suitable drug like properties, and, 
potentially, with promising prospects for the future. In previous studies, RI-OR2-TAT 
has been shown to effectively inhibit the formation of both Aβ oligomers and fibrils, 
as demonstrated by several different in vitro and in vivo experimental systems.  
Apart from its ability to inhibit the formation of Aβ oligomers, some other important 
properties of this RI-peptide are its ability to pass through the BBB, and its stability in 
the blood circulation due to its high resistance to proteolysis (Parthsarathy et al., 
2013). 
In the current project, the main objective was to establish a nano carrier 
technology for our RI-peptide inhibitors. Previously, we have developed a promising 
new drug which we call a Peptide Inhibitory NanoParticle (PINP). This consists of 
cholesterol/sphingomyelin PEGylated nanoliposomes to which the retro-inverted 
peptide RI-OR2-TAT (Ac-rGffvlkGrrrrqrrkkrGyc-NH2) has been attached by ‘click 
chemistry’. Previous work has indicated that PINPs are able to block the formation of 
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aggregated forms of Aβ in vitro and in vivo (Gregori et al., 2015 manuscript 
submitted). The initial development of these PINPs was carried out by a group in 
Milan, Italy, at the University of Milano-Bicocca, led by Prof. Massimo Masserini and 
Dr. Maria Gregori, and one of the main objectives of this work was to transfer the 
technology needed to make these PINPs to our group at Lancaster. This project was 
approached in three distinct stages, involving the manufacture and characterization 
of simple liposomes, PEGylated liposomes, and, finally, the PINPs themselves. Each 
type of liposome was developed in three different sizes (50, 100 and 200 nm). These 
various types of liposomes were characterized by size using DLS, shape-ultrastructure 
using TEM, and were also examined for their ability to affect Aβ aggregation, and to 
protect against Aβ cytotoxicity.  
The use of PINPs as a potential drug for the treatment of AD, instead of the 
free peptide, was an attempt to improve the efficacy of the peptide inhibitor. In 
previous experiments by Dr. Mark Taylor at Lancaster University, the potency of the 
two types of drugs (RI-OR2-TAT and PINPs) was tested and compared, and the results 
suggested that the PINPs had more potency and increased efficacy against Aβ 
aggregation. There are several reasons as to why this might be the case.  
The presence of multiple copies of the RI-peptide on the surface of the 
nanoliposomes, would allow their simultaneous interaction with oligomeric forms of 
Aβ, and this should result in more potent inhibition of aggregation, due to the effects 
of multivalency. According to a previous study, Chafekar and his colleagues observed 
that four KLVFF linked together by a dendrimer scaffold inhibit Aβ aggregation more 
effectively the than the monomeric KLVFF peptide. Consequently, in the case of 
PINPs, where there are many more copies of the RI-peptide, this inhibition is 
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expected to be even more effective (Chafekar et al., 2007). Another possible 
explanation for the increase potency of PINPs is based on their electrical charge. We 
have calculated that each PINP with approximately 100 nm has ~ 1690 RI-OR2-TAT 
molecules attached onto its surface, and this RI-peptide contains many positively 
charged amino acids residues. This means that the surface of each PINP would have a 
high positive charge which could help to attract and capture Aβ monomers or 
multimers (Gregori et al., 2015 manuscript submitted). Additionally, it is possible 
that, once captured, Aβ inserts into the lipid component of the liposomes, and so is 
effectively removed from solution. It is well known that Aβ oligomers and pre-fibrils 
of Aβ 1-42 insert into the lipid component of cell membranes (Morita et al., 2012). 
 
6.2 Findings of the study 
The main goal of this project was the creation of simple liposomes, which were 
then combined with the peptide inhibitor RI-OR2-TAT to create the PINPs. However, 
the part of this study most in common with other published work is based on 
development of the preparation method for the liposomes, and their subsequent 
characterization, based on their size and shape-ultrastructure. Previous investigators 
have reported that DLS is a quick and easy method to measure the size of liposomes, 
ranging from 50 nm to 200 nm, which is why we chose it as a suitable technique in 
the current project (Matsuzaki et al., 2000; Morton et al., 2012). TEM with negative 
staining is also a well-established method for determining the size, ultrastructure, as 
well as the lamellarity of liposomes (Chetanachan et al., 2008) and in our study this 
technique also proved to be a suitable for revealing the ultrastructure of liposomes. 
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6.2.1 Creation of liposomes in three distinct sizes  
For the manufacture of the three different sizes (50, 100, 200 nm) of 
liposomes, the use of polycarbonate membranes (PM) of different pore sizes was 
necessary. After the extrusion of the liposome suspensions through these PMs, they 
were examined by DLS. These DLS measurements confirmed that three different 
sizes of nanoliposomes were produced. Furthermore, the measurements of standard 
gold nanoparticles showed DLS is able to measure the size of nanoparticles 
reasonably accurately, including those with a small diameter (figure 3.8). 
 In the current study, hydration of a thin lipid film was applied for the 
preparation of liposomes: i.e. the Bangham method. In other studies, alternative 
methods have been used, such as: the reverse-phase evaporation (REV) technique; 
the solvent (ether or ethanol) injection technique; and detergent dialysis (Laouini et 
al., 2012; Akbarzadeh et al., 2013). According to (Meure et al., 2008; Dua et al., 2012) 
all of the above techniques have their advantages and disadvantages. Some of the 
main drawbacks of all of the above techniques are: they are time consuming, they 
have sterilization issues, they result in a high percentage of heterogeneity with 
regard to the size of the vesicles, and large amount of organic solvent is required. 
Furthermore, the ethanol/ether injection and reverse-phase evaporation (REV) 
techniques present some further limitations, such as: low drug stability, unsuitable 
for drug encapsulation, low yield, as well as poor entrapment efficiency.  On the 
other hand, hydration of a thin lipid film by the Bangham method, despite its 




With regard to the extrusion of liposomes, Morton and colleagues have used a 
Liposofast LF-50 extruder, instead of Avanti’s mini extruder which was used in our 
study (Morton, et al., 2012). The use of the Liposofast LF-50 extruder has some 
advantages since it is, practically, an easier and more effective technique. Two of the 
most important advantages of this extruder are, firstly, that specific and reproducible 
nitrogen pressure is used for each pore size (e.g. 25 psi for 400 nm liposomes, 125 psi 
for 100- nm liposomes, and 400-500 psi for 30 nm liposomes), while Avanti’s mini 
extruder is operated by hand. Secondly, the Liposofast LF-50 extruder allows the 
preparation of liposomes up to 50 mL in volume, while the maximum volume of 
liposomes that can be prepared using Avanti’s mini extruder is only 1 mL (Morton et 
al., 2012).  Clearly, the replacement of our extrusion method with the Liposofast LF-
50 extruder would be advantageous. 
 
6.2.2 DLS investigation 
DLS enabled us to examine the size of the three types of liposomes. Following 
techniques published previously using DLS (Santos et al., 2010; Cho et al., 2013), the 
ideal number of passages (11 passages) required to achieve a correct and consistent 
size of liposomes was defined in our study. An increase in number of up to 14 
passages was tried, but without any significant change compared with liposomes 
which underwent 11 passages (see figure 3.13). 
Additionally, by the use of DLS, it was possible to investigate how the different 
concentrations of the liposome suspensions might affect their size measurement. 
Furthermore, DLS also revealed that the measurement of nanoparticles which are 
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positively charged, in our case, can affect the final results by giving an erroneous 
value from their normal size due to their increased hydrodynamic diameter. DLS also 
helped us to examine the stability of the three different types and sizes of liposomes 
and suggested that they are stable for more than two months, especially the 
liposomes of 100 nm diameter. 
Another experiment which was carried out and examined by DLS is the size 
measurement of liposomes after extrusion at high temperature. According to the 
fluid mosaic model of cell membranes, the presence of cholesterol plays a regulatory 
role in maintaining the fluidity of the membrane at normal levels in extreme 
conditions such as low and high temperatures. High temperatures can cause 
fluidization, while low temperatures can cause rigidification of the membrane (Los 
and Murata, 2004). In this study, measurements, by, DLS of liposomes extruded at 
75°C were determined, and this confirmed, how high temperatures can affect the 
fluidity of the liposomal membrane. This may be due to a change in the steroid ring 
of cholesterol, which becomes more bulky and increases the density of the 
hydrophobic section of the membrane as temperature increases.  
However, it is important to note that, DLS is a somewhat variable technique, 
giving different values each time using the same sample. For example for the 100 nm 
liposomes, the same sample can give two different values (119 nm and 109.2 nm). 
According to Morton and colleagues, who prepared liposomes of various 
compositions using more than two lipids in different combinations, Nanoparticle 
Tracking Analysis (NTA) gives more accurate results than DLS. A possible explanation 
is that NTA gives an indication of size due to rate of movement in solution (Brownian 
motion) rather than physical measurement of actual dimensions (Morton et al., 
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2012). In other words, NTA is able to measure the size of each nanoliposome from 
direct observations of diffusion in a liquid medium, independent of particle refractive 
index or density. However, our laboratory does not have access to NTA, which could 
have been used as complementary technique alongside DLS.   
 
6.2.3 TEM investigation 
TEM was employed as a complimentary method to DLS and provided more 
information about the nanoliposomes, based on their size, shape and ultrastructure. 
The three types of nanoliposomes were easily imaged by applying negative staining 
and many characteristics which were impossible to observe using DLS, were revealed 
using TEM.  
One of the most important findings using TEM was the way that the liposomes 
are arranged in the space at high and low concentrations. At high concentrations, 
liposomes have a tendency to come together and form clumps of liposomes. This 
would help to explain why the measurement of samples at high concentrations using 
DLS can sometimes give erroneous measurements. So, by use of TEM, we have 
highlighted the disadvantage of use of concentrated samples in DLS measurements.  
In contrast, samples with lower concentration did not form clumps when examined 
by TEM and their shape and size could be accurately determined using both TEM and 
DLS.  
In addition, another important finding that TEM revealed was the lamellarity of 
the liposomes. The preparation method for the liposomes, as well as affecting their 
size and shape, also has an influence on their lamellarity. According to Traïkia et al. 
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(2000) and Supaporn, (2011) the freeze thawing and sonication methods helps the 
creation of unilamellar vesicles from multilamellar vesicles. The majority of the 
micrographs of liposomes presented above, showed a multilamellar structure (e.g. 
figures 4.3, 4.6, 4.8), which is something that must be taken into consideration in the 
future for further refinement of the method for preparation of the liposomes. In 
contrast, the samples that had undergone freeze thawing and sonication showed a 
unilamellar structure, confirming that the use of these two techniques is needed to 
make unilamellar liposomes.  For our purposes, due to the fact that the only the 
outer surface of each liposome is decorated with inhibitory peptide, monolamellar 
structures would be highly preferable.  
Another complementary technique along with TEM and DLS which could reveal 
important  information about liposome size (diameter and height), morphology, 
surface properties, and changes in these characteristics during storage, is atomic 
force microscopy (AFM), which allows the visualization of nanoliposomes without 
any change in their physiological form (Ruozi et al., 2011). Ruozi et al. (2011) when 
comparing AFM with other techniques such as environmental scanning electron 
microscopy (ESEM), transmission electron microscopy (TEM) and confocal laser 
scanning microscopy (CLSM) for examination of liposome structure, these authors 
concluded that each of these microscopic techniques reveals its own unique 
information for the characterization of liposomes. For example, AFM gives 
information on the shape, morphology, dimensions and surface properties of 
liposomes; - TEM reveals information regarding their shape, morphology and 
dimension; while ESEM and CLSM reveal information regarding the dimensions and 
internal structure of liposomes, respectively. 
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In summary, TEM investigation was able to determine the basic characteristics 
of liposomes (size, shape and ultrastructure), but was unable to distinguish between 
the three types of liposomes (simple, PEGylated liposomes and PINPs). However, 
TEM was a suitable technique to characterize our liposome physical structures.   
 
6.2.4 MTS and Th-T assays investigation  
In order to test whether the three types of liposomes were toxic to 
neuroblastoma (SH-SY5Y) cells, they were incubated with the cells at different 
concentrations, in complete medium (DMEM), for 24 h. According to our results, the 
three types of liposomes proved not to be toxic to cells and their presence at 
different concentrations did not affect the growth of SHSY-5Y cells, although some 
slight stimulation of growth was observed, and this might even be statistically 
significant in some cases. This could be due simply to the supply of lipids for 
incorporation into cell membranes of cells. Furthermore, using the MTS assay on SH-
SY5Y cells grown in the presence of different concentrations of PINPs it was proved 
that they were able to protect against the damaging toxic effects of Aβ, while simple 
and PEGylated liposomes were unable to do this. This confirms that the presence of 
RI-OR2-TAT peptide is required. 
Additionally, from the Th-T assay, we did not manage to get expected results 
for PINPs but comparing them with PEGylated liposomes, PINPs did show some 
inhibition to the aggregation of Aβ, especially when present at high concentrations. 
However, it is important to mention that the Th-T assay proved to be very variable, 
giving different values each time, nanoliposomes (PINPs) are not mixed well with Aβ 
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and sometimes the Aβ failed to aggregate, resulting in erroneous and unreliable 
data. 
6.2.5 Cell penetration investigation  
As referred to in the results section (cell penetration), the aggregation of Aβ 
starts inside cells and then extends to the exterior (Takahashi et al., 2002). For that 
reason the candidate drug (PINPs), in addition to its ability to pass through the BBB, 
must be also able to penetrate into cells and inhibit Aβ aggregation or prevent the 
release of it outside of the cell. In our cell penetration assay both PEGylated 
liposomes and PINPs were tested at various concentrations and it was revealed that 
they are both able to penetrate into neuroblastoma SHSY-5Y cells. However, PINPs 
showed a greater efficiency to penetrate into cells due to presence of the ‘TAT’ 
transit sequence. The trans-activating transcriptional activator (TAT) peptide is the 
most commonly used cell penetration peptide in biological systems. ‘TAT’ is derived 
from the transcriptional activator protein present in HIV type 1 (Torchilin, 2008; 
Jeang et al., 1999). In agreement with our data, a previous study (Torchilin et al., 
2001) has revealed that large drug carriers (200 nm liposomes) incorporating the 









An overview of the main characteristics of the three types of liposomes made here 
is shown in table below.  
 TYPES OF LIPOSOMES 
Characteristics Simple liposomes PEGylated 
liposomes 
PINPs 
Toxic to SHSY-5Y 
cells 
   
Able to rescue 
SHSY-5Y cells from 
Aβ toxicity 
   
Ability to inhibit Aβ 
oligomer formation 
   
Ability to penetrate 
into the SHSY-5Y 
cells 
-   
Table 6.1: This table shows the main characteristics of the three types of liposomes which revealed 
from the methods which were applied in the current study.  
 
6.3 Study’s limitations  
As we know, each scientific study has many possible limitations which can 
affect the study. I will refer to the most important limitations which had the greatest 
potential impact on the quality of my results, as well as those limitations which had a 
potential impact on my ability to answer the main objectives of my project. The 
majority of the limitations in the current study relate to the experimental procedures 
that were used during the production of the liposomes.  
The first limitation was the extrusion of liposomes which was carried out using 
the Avanti’s mini extruder; the second limitation was the multiple transfers of the 
liposome suspensions into many different vials before the final stage, involving 
purification of PINPs by gel filtration column chromatography, could be carried out; 
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finally, Steward’s method for determination of lipid content did not work well. All of 
the above limitations affected my results, both qualitatively and quantitatively. The 
Avanti’s mini extruder for the preparation of liposomes permits a maximum volume 
that can be extruded of only 1 mL per batch. This is an important limitation because 
the bulk production of liposomes, for larger scale experiments or for preclinical 
research, is impractical. Also, multiple passages of the lipids through the membrane 
is time consuming, and increases the risk of contaminating the lipid suspensions with 
bacteria. In addition, the many transfers of the liposome suspension from vial to vial, 
as well as the column chromatography method for the separation of PINPS from the 
unbound peptide, resulted in a substantial proportion of the lipids being lost each 
time. This was confirmed by the use of the WAKO phospholipid assay. These 
limitations, apart from the quantitative consequences for the results presented here, 
would have a negative impact on the production of liposomes for commercial 
purposes, including the cost of their preparation as a potential drug. Consequently, 
in order to improve the quality and to limit the waste of lipids, the replacement of 
mini extruder with Liposofast LF-50 extruder is recommended.  
With regard to Steward’s method for lipid determination, which was required 
in order to determine the phospholipid recovery of liposomes after extrusion, this 
could not be used in the current study for technical reasons (lack of the suitable 
equipment-specific glass cuvettes). It was therefore necessary to use an alternative 
technique (WAKO assay). In Stewart’s assay, phospholipids (sphingomyelin) form a 
complex with ammonium ferrothiocyanate. An important advantage of the Stewart’s 
assay comparing with a similar assay (Barlett assay) is that any inorganic phosphate 
does not interfere and therefore PBS buffer can be used. On the other hand, the 
142 
 
WAKO assay is a practically easier and quicker technique. This assay is based on an 
enzymatic reaction using N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline 
(DAOS) as a blue pigment. Both phospholipid assays have the similar level of 
sensitivity, and so the WAKO assay did prove to be a suitable alternative to Stewart’s 
assay. 
  
6.4 Future prospective 
It is clear that there is a need for further investigation and optimization of this 
study in order to yield reproducible and reliable results, but also to reach to the 
desired goal, which is further research in vivo. The current project presented 
important results for the structure and size of liposomes, and also their ability to 
inhibit Αβ toxicity and aggregation. It is important to mention again that the current 
study examined three types of liposomes of three distinct sizes. Some further 
experiments which could be carried out in future studies are presented below: 
Examination of the three different sizes of PINPs crossing the BBB 
Following on from the preparation the three different sizes of liposomes, 
further experiments are possible to investigate their differential properties. An 
interesting experiment would be to examine the ability of the three different sizes of 
nanoliposomes to pass through the BBB.  This could be carried out most easily by 
using an artificial BBB model, such as the monolayer of hCMEC/D3 cells described by 
(Salvati et al. (2013). Here, PINPs and liposomes are applied to one the side of the 
cell monolayer, and then attempts are made to detect them on the other side, which 
reveals trancytosis of the nanoliposomes through the artificial BBB. This technique 
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was employed by Dr. Salvati and colleagues to show that PINPs of a standard size 
(100 nm) can effectively cross the BBB.  
The optimal size of nanoparticles as drug delivery systems is something that 
has concerned many scientists. The appropriate size of nanoparticles and specifically 
nanoliposomes, should not be too large or too small. According to previous work, 
liposomes smaller than 100 nm have a longer half-life in the blood circulation and 
fewer interactions with plasma proteins. In contrast, larger nanoliposomes (~200-300 
nm) have an increased drug holding capacity, but a shorter half-life in the blood 
circulation because they are rapidly removed by the RES (Bozzuto and Molinari 2015; 
Fanciullino and Ciccolini 2009). Based on this type of information, the appropriate 
size for nanocarriers is generally thought to be in the range 100-150 nm. However, it 
would be interesting to examine the relative merits of the three distinct sizes of our 
liposomes produced here as potential drugs. 
Lactate dehydrogenase (LDH) assay 
As regards the ability of liposomes to affect Aβ aggregation and protect against 
cytotoxicity, neither the simple nor the PEGylated liposomes showed any positive 
results. In contrast, PINPs showed positive and promising results for the inhibition of 
Aβ toxicity towards neuronal cells in this study, as assessed by the MTS assay. It 
would be useful to confirm this by use of alternative techniques, such as the Lactate 
dehydrogenase (LDH) assay. This assay measures cell proliferation rather than cell 
survival, giving a different perspective on the protective effect of PINPs towards cells. 
Production of liposomes using tetradecanol-1 lipid as alternative to cholesterol 
Other studies have used various different compositions of lipids for the 
development of liposomes (Franzen et al., 2011). According to a previous study (Ali 
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et al., 2010) fatty alcohols, and specifically tetradecanol-1, can be used as an 
alternative to cholesterol in lipid based drug delivery. Cholesterol and tetradecanol-1 
have similar chemical and biological properties and so they behave in a similar way in 
the liposomal membranes. However, the formation of liposomes using fatty acid 
alcohols as an alternative to cholesterol has revealed some differential results when 
they are examined for parameters such as drug loading and drug release. Liposomes 
made with tetradecanol-1 were found to shown to be better for drug delivery, 
compared to those containing cholesterol (Ali et al., 2010). In addition, another 
reason why tetradecanol-1 may be a more suitable lipid than cholesterol is due to 
the fact that cholesterol has some issues with contamination, because of its source 
(usually from animals). Consequently, we should consider the use of tetradecanol-1 
as an alternative to cholesterol in development of PINPs as a drug. 
Encapsulation of peptide inhibitor in the interior side of the liposome 
Based on previous information, the presence of tetradecanol-1 in the 
liposomes has a positive impact on drug loading and drug release, and this could lead 
to evolution of a more potent and safer version of our drug (Ali et al., 2010). 
Moreover, other approaches have involved encapsulation of the drug into the 
interior space of the liposomes, instead of incorporating it onto their surface (Hu et 
al., 2010). So, we might be able to produce a more effective drug by using a 
combination of drug delivery systems, involving incorporation of the RI-peptide onto 
the surface of the liposomes, as well as by inserting it into the liposome core. This 
new type of ‘dual delivery’ mechanism would then be tested in various in vitro and in 
vivo experimental systems. The encapsulation of the RI-peptide inhibitor into the 
core of the liposomes could also create a safer drug since the peptide inhibitor would 
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not be able to evoke any adverse immune reactions during its circulation throughout 
the body. 
Storage of PINPs 
A basic rule for the development of any drug is for it to be stable for a long time, 
either at room temperature or at 4°C. According to the results that we obtained for 
the three types of nanoliposomes, their stability in terms of size, as measured by DLS, 
was maintained for some months. However, desiccation (freeze-drying) of the drug 
prior to its reconstitution as a liquid, when required, could be advantageous for long-
term storage. The general idea is to remove the moisture from the liquid suspension 
of liposomes. Based on a previous study by Misra et al (2009), the conversion of 
liquid liposomes to a liposomal dry powder formulation (LDPF) is an efficient and 
simple technique which can be used to enhance the stability of the drug. Here, the 
homogenized liposome solution is dispersed into a suitable carrier and then 
converted to powder form by using freeze drying, spray drying or spray freeze drying. 
In addition, the conversion of drug from liquid form to powder form can change the 
route for drug administration (e.g. from injected drug to inhaled drug therapy), 
making it easier for patients to administer. 
 Complementary technique of TEM (Transmission Electron using freeze fracturing) 
A previous study (Gradauer et al., 2012) has involved the characterization of 
liposome samples using two powerful techniques: negative stain EM and freeze 
fracture EM. Both of them revealed important information about the liposomes, but 
the freeze fracture technique is recommended for characterization of liposomes by 
shape or surface modification. Consequently, in the current study it would have been 
advantageous to use freeze fracture EM as a complementary method of visualization 
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in order to reveal more accurate information about the morphology of various types 
of liposomes (Misra et al., 2009).  
Centrifugation using Vivaspin 6 an alternative of column purification  
As referred above, one of the most important limitations of the current study 
was that during the preparation of PINPs we lost a substantial quantity of the lipids 
from the many transfers between vials, and also from the separation of PINPs from 
unbound peptide using column chromatography. Consequently, a promising 
technique that may lead to fewer losses is to replace the column purification by 
centrifugation of the liposome suspension using Vivaspin 6 tubes. Vivaspin 6 tubes 
are specially designed tubes, with a membrane which would leave the more 
concentrate sample (PINPs) in the upper chamber, while the solvent and the less 
concentrated sample (filtered PBS and unbound peptide) should pass through the 
membrane. 
 
6.5 Conclusion  
In conclusion, the main objective of the current study was the development of 
the methods required for the production and characterization of three different 
types of liposomes, in three distinct sizes (200, 100 and 50 nm), as a means of 
transferring the technology for production of nanoliposomes and PINPs to our 
laboratory in Lancaster. The original method for liposome preparation was 
developed at The University of Milano-Bicocca, by Professor Massimo Masserini and 
Dr. Maria Gregori. Based on the work presented here, we are now able to produce 
the liposomes by ourselves, giving us the ability in future to manufacture the drug 
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(PINPs), and any future derivatives or modifications, at Lancaster. The three different 
sizes and types of liposomes were characterized by size, shape-ultrastructure, and 
examined for their ability to inhibit the aggregation and the toxicity of Aβ, and their 
ability to penetrate into SHSY-5Y neuroblastoma cells. According to the results, these 
different types of liposomes were prepared according to plan, and lead us to the 
conclusion that only PINPs, and not the other two types of liposomes, are able to 
inhibit the aggregation and toxicity of Aβ. Additionally, TEM and DLS were the two 
powerful techniques used for this study, and helped us to understand how to 
prepare liposomes of suitable size and appearance (shape and ultrastructure). 
To sum up, the current study constitutes an important step in the evolution 
and improvement of our drug (PINPs), hopefully to the point where it can fulfill its 
promise as a prospective treatment for AD. Moreover, the study of nanoliposomes 
has brought us into contact with the field of nanomedicine, which is an exciting and 
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